<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">82690</article-id><article-id pub-id-type="doi">10.7554/eLife.82690</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Evidence for virus-mediated oncogenesis in bladder cancers arising in solid organ transplant recipients</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-157914"><name><surname>Starrett</surname><given-names>Gabriel J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5871-5306</contrib-id><email>gabe.starrett@nih.gov</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293460"><name><surname>Yu</surname><given-names>Kelly</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293461"><name><surname>Golubeva</surname><given-names>Yelena</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-293462"><name><surname>Lenz</surname><given-names>Petra</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-293463"><name><surname>Piaskowski</surname><given-names>Mary L</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8453-6416</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293464"><name><surname>Petersen</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-29104"><name><surname>Dean</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293465"><name><surname>Israni</surname><given-names>Ajay</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293466"><name><surname>Hernandez</surname><given-names>Brenda Y</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293467"><name><surname>Tucker</surname><given-names>Thomas C</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-261588"><name><surname>Cheng</surname><given-names>Iona</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293468"><name><surname>Gonsalves</surname><given-names>Lou</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293469"><name><surname>Morris</surname><given-names>Cyllene R</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293470"><name><surname>Hussain</surname><given-names>Shehnaz K</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293471"><name><surname>Lynch</surname><given-names>Charles F</given-names></name><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-276923"><name><surname>Harris</surname><given-names>Reuben S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9034-9112</contrib-id><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-125431"><name><surname>Prokunina-Olsson</surname><given-names>Ludmila</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9622-2091</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165483"><name><surname>Meltzer</surname><given-names>Paul S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-31561"><name><surname>Buck</surname><given-names>Christopher B</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3165-8094</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-293472"><name><surname>Engels</surname><given-names>Eric A</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id><institution>CCR, NCI, NIH</institution></institution-wrap><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id><institution>DCEG, NCI, NIH</institution></institution-wrap><addr-line><named-content content-type="city">Rockville</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/012cvds63</institution-id><institution>Leidos Biomedical Research Inc</institution></institution-wrap><addr-line><named-content content-type="city">Frederick</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/017zqws13</institution-id><institution>Department of Medicine, Nephrology Division, Hennepin Healthcare System, University of Minnesota</institution></institution-wrap><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03tzaeb71</institution-id><institution>Cancer Center, University of Hawaii</institution></institution-wrap><addr-line><named-content content-type="city">Honolulu</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02k3smh20</institution-id><institution>The Kentucky Cancer Registry, University of Kentucky</institution></institution-wrap><addr-line><named-content content-type="city">Lexington</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Department of Epidemiology and Biostatistics,and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco</institution></institution-wrap><addr-line><named-content content-type="city">Fremont</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03cqd3e64</institution-id><institution>Connecticut Tumor Registry, Connecticut Department of Public Health</institution></institution-wrap><addr-line><named-content content-type="city">Hartford</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05rrcem69</institution-id><institution>California Cancer Reporting and Epidemiologic Surveillance Program, University of California, Davis</institution></institution-wrap><addr-line><named-content content-type="city">Davis</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pammg90</institution-id><institution>Cedars-Sinai Cancer and Department of Medicine, Cedars-Sinai Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Los Angeles</named-content></addr-line><country>United States</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/036jqmy94</institution-id><institution>The Iowa Cancer Registry, University of Iowa</institution></institution-wrap><addr-line><named-content content-type="city">Iowa City</named-content></addr-line><country>United States</country></aff><aff id="aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/017zqws13</institution-id><institution>Howard Hughes Medical Institute, University of Minnesota</institution></institution-wrap><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Wallace</surname><given-names>Nicholas</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05p1j8758</institution-id><institution>Kansas State University</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>El-Deiry</surname><given-names>Wafik S</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05gq02987</institution-id><institution>Brown University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>24</day><month>03</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e82690</elocation-id><history><date date-type="received" iso-8601-date="2022-08-13"><day>13</day><month>08</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-03-22"><day>22</day><month>03</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2021-11-11"><day>11</day><month>11</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.11.11.21266080"/></event></pub-history><permissions><ali:free_to_read/><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><ali:license_ref>http://creativecommons.org/publicdomain/zero/1.0/</ali:license_ref><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0 public domain dedication</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-82690-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-82690-figures-v2.pdf"/><abstract><p>A small percentage of bladder cancers in the general population have been found to harbor DNA viruses. In contrast, up to 25% of tumors of solid organ transplant recipients, who are at an increased risk of developing bladder cancer and have an overall poorer outcomes, harbor BK polyomavirus (BKPyV). To better understand the biology of the tumors and the mechanisms of carcinogenesis from potential oncoviruses, we performed whole genome and transcriptome sequencing on bladder cancer specimens from 43 transplant patients. Nearly half of the tumors from this patient population contained viral sequences. The most common were from BKPyV (N=9, 21%), JC polyomavirus (N=7, 16%), carcinogenic human papillomaviruses (N=3, 7%), and torque teno viruses (N=5, 12%). Immunohistochemistry revealed variable Large T antigen expression in BKPyV-positive tumors ranging from 100% positive staining of tumor tissue to less than 1%. In most cases of BKPyV-positive tumors, the viral genome appeared to be clonally integrated into the host chromosome consistent with microhomology-mediated end joining and coincided with focal amplifications of the tumor genome similar to other virus-mediated cancers. Significant changes in host gene expression consistent with the functions of BKPyV Large T antigen were also observed in these tumors. Lastly, we identified four mutation signatures in our cases, with those attributable to APOBEC3 and SBS5 being the most abundant. Mutation signatures associated with an antiviral drug, ganciclovir, and aristolochic acid, a nephrotoxic compound found in some herbal medicines, were also observed. The results suggest multiple pathways to carcinogenesis in solid organ transplant recipients with a large fraction being virus-associated.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>polyomavirus</kwd><kwd>papillomavirus</kwd><kwd>bladder cancer</kwd><kwd>torque teno virus</kwd><kwd>solid organ transplant recipient</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>Intramural Research Program</award-id><principal-award-recipient><name><surname>Starrett</surname><given-names>Gabriel J</given-names></name><name><surname>Engels</surname><given-names>Eric A</given-names></name><name><surname>Buck</surname><given-names>Christopher B</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Nearly half of bladder cancers of solid organ transplant recipients harbor papillomaviruses or polyomaviruses, with many tumors showing evidence of clonal viral integration and viral oncogene effects on tumor gene expression patterns.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>At least 20% of all cancers are attributable to viral, bacterial, or parasitic infections (<xref ref-type="bibr" rid="bib25">de Martel et al., 2020</xref>). The advent of high-throughput deep sequencing has provided unprecedented opportunities to learn how infectious agents are involved in cancer in an unbiased manner. Several previous studies have searched for microbial nucleotide sequences in The Cancer Genome Atlas (TCGA), the International Cancer Genome Consortium (ICGC), and PanCancer Analysis of Whole Genomes (PCAWG) datasets (<xref ref-type="bibr" rid="bib100">Zapatka et al., 2020</xref>; <xref ref-type="bibr" rid="bib13">Cantalupo et al., 2018</xref>). In addition to confirming known associations, such as the presence of human papillomaviruses (HPVs) in cervical cancer, these studies also uncovered rare cases in which viral sequences were unexpectedly found in other major cancers affecting the general population (<xref ref-type="bibr" rid="bib13">Cantalupo et al., 2018</xref>).</p><p>Despite the immense amount of tumor sequencing data generated to date, the identification of microorganisms in common cancers through these studies has been limited. A more focused assessment of groups at increased risk for virus-associated cancers may be needed. In particular, oncogenic viruses may contribute to a larger fraction of cancer cases among immunosuppressed individuals, such as those with human immunodeficiency virus (HIV) infection and organ transplant recipients. These populations have been previously shown to be at increased risk for developing papillomavirus-mediated cancers, and oncogenic viruses, such as Kaposi’s sarcoma-associated herpesvirus and Merkel cell polyomavirus (MCPyV), were discovered in these patient populations (<xref ref-type="bibr" rid="bib14">Chang et al., 1994</xref>; <xref ref-type="bibr" rid="bib30">Feng et al., 2008</xref>; <xref ref-type="bibr" rid="bib21">D’Arcy et al., 2021</xref>).</p><p>Roughly a dozen ‘high-risk’ HPV types cause nearly all cervical cancers, a large majority of other anogenital cancers, and about half of all oropharyngeal cancers (<xref ref-type="bibr" rid="bib33">Graham, 2017</xref>). The carcinogenic effects of these small circular double-stranded DNA viruses are primarily dependent on the expression of the E6 and E7 oncogenes which, among a wide range of other functions, inactivate the tumor suppressor proteins p53 and Rb, respectively (<xref ref-type="bibr" rid="bib67">Rosty et al., 2005</xref>; <xref ref-type="bibr" rid="bib17">Crook et al., 1991</xref>; <xref ref-type="bibr" rid="bib52">Mirabello et al., 2017</xref>; <xref ref-type="bibr" rid="bib22">DeCaprio, 2014</xref>; <xref ref-type="bibr" rid="bib6">Barbosa et al., 1990</xref>).</p><p>Polyomaviruses share many biological features with papillomaviruses. In particular, polyomavirus T antigens perform many of the same functions as papillomavirus oncoproteins and are similarly oncogenic in cellular and animal models (<xref ref-type="bibr" rid="bib53">Moens and Macdonald, 2019</xref>). MCPyV has been identified as an etiological factor in a rare skin cancer, Merkel cell carcinoma (<xref ref-type="bibr" rid="bib30">Feng et al., 2008</xref>; <xref ref-type="bibr" rid="bib72">Shuda et al., 2008</xref>; <xref ref-type="bibr" rid="bib39">Kassem et al., 2008</xref>). Another human polyomavirus, BKPyV, has a long-debated history as a candidate cancer-causing virus. Several case reports have described the detection of BKPyV in bladder cancers arising in transplant recipients, and kidney recipients who develop BKPyV viremia or BKPyV-induced nephropathy (BKVN) after transplant are at increased risk of bladder cancer (<xref ref-type="bibr" rid="bib35">Gupta et al., 2018</xref>; <xref ref-type="bibr" rid="bib86">Vajdic and van Leeuwen, 2009</xref>; <xref ref-type="bibr" rid="bib46">Li et al., 2021</xref>; <xref ref-type="bibr" rid="bib59">Papadimitriou et al., 2016</xref>).</p><p>Similar to HPV-induced cervical and oropharyngeal cancers, bladder cancers exhibit somatic point mutations that are largely attributable to the activity of APOBEC3 family cytosine deaminases (<xref ref-type="bibr" rid="bib66">Robertson et al., 2017</xref>; <xref ref-type="bibr" rid="bib9">Burns et al., 2013</xref>; <xref ref-type="bibr" rid="bib65">Roberts et al., 2013</xref>). These enzymes normally function as innate immune defenses against viruses by deaminating cytosines in single-stranded DNA, leading to hypermutation of the viral genome (<xref ref-type="bibr" rid="bib62">Poulain et al., 2020</xref>). Commonly, APOBEC3 enzymes, particularly APOBEC3A and APOBEC3B, can become dysregulated and cause carcinogenic damage to cellular DNA during the development of various types of cancer (<xref ref-type="bibr" rid="bib80">Swanton et al., 2015</xref>). APOBEC3A and APOBEC3B are upregulated in response to the expression of HPV E6 and E7, and APOBEC3A can restrict HPV replication (<xref ref-type="bibr" rid="bib54">Mori et al., 2017</xref>; <xref ref-type="bibr" rid="bib97">Warren et al., 2017</xref>; <xref ref-type="bibr" rid="bib1">Ahasan et al., 2015</xref>; <xref ref-type="bibr" rid="bib96">Warren et al., 2015b</xref>; <xref ref-type="bibr" rid="bib91">Vieira et al., 2014</xref>). The large T antigens (LTags) of BKPyV and JC polyomavirus (JCPyV, a close relative of BKPyV) also upregulate APOBEC3B expression and activity (<xref ref-type="bibr" rid="bib76">Starrett et al., 2019</xref>; <xref ref-type="bibr" rid="bib60">Peretti et al., 2018</xref>; <xref ref-type="bibr" rid="bib88">Verhalen et al., 2016</xref>).</p><p>To characterize the mutational, transcriptomic, and viral landscapes of bladder cancers arising in immunosuppressed individuals, we evaluated archived tissues from 43 solid organ transplant recipients who developed this malignancy. We performed total RNA sequencing and whole genome sequencing (WGS) from these tissues. We utilized high-sensitivity methods and comprehensive reference databases of sequences for conserved viral proteins to identify known viral species and to search for divergent viruses. Once viruses were identified, we further evaluated the sequence data for integration events, point mutations, mutation signatures, and differentially expressed genes to identify differences correlating with the presence of these viruses and their integration state.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Bladder cancers from transplant recipients</title><p>The study population was comprised of 43 U.S. cases from patients who developed bladder cancer after receiving solid organ transplantation (<xref ref-type="table" rid="table1">Table 1</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>). Seventy percent were male and 70% were non-Hispanic white. The median age at cancer diagnosis was 65 years (range: 27–82). The most commonly transplanted organ was the kidney (56%), followed by the heart and/or lung (33%) and liver (9%). Primary tumors were roughly an equal mixture of high- and low-grade carcinomas diagnosed with a median of 5.7 years after transplantation. Twelve cases were categorized as in situ as defined by the Surveillance, Epidemiology, and End Results (SEER) Program, with two of those cases being transitional cell carcinomas in situ and ten cases being noninvasive papillary transitional cell carcinomas. Invasive cases were mostly categorized into the localized stage (n=20, 46%), which includes tumors that have invaded into the mucosa, submucosa, muscle, or subserosa. The 11 remaining cases either had regional or distant invasion or metastasis. We successfully generated WGS data for 38 primary tumors, three metastases, and 10 normal (histologically non-malignant) tissues, with a median of 31 x coverage across the human genome (range: 14–55 x) (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>). We generated total RNA sequencing data for 43 primary tumors, five metastases, and 14 normal tissues, with a median of 30 million reads per sample (range: 4–65.5 million).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Characteristics of post-transplant bladder cancer cases (N=43).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Characteristic</th><th align="left" valign="top" colspan="2">Statistic</th></tr></thead><tbody><tr><td align="left" valign="top"/><td align="left" valign="top"><bold>Median</bold></td><td align="left" valign="top"><bold>IQR</bold></td></tr><tr><td align="left" valign="top">Age in years at diagnosis</td><td align="char" char="." valign="top">65</td><td align="char" char="." valign="top">60, 71</td></tr><tr><td align="left" valign="top">Years from transplant to diagnosis</td><td align="char" char="." valign="top">5.8</td><td align="char" char="." valign="top">3, 7</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top"><bold>N</bold></td><td align="char" char="." valign="top"><bold>%</bold></td></tr><tr><td align="left" valign="top">Sex</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Female</td><td align="char" char="." valign="top">13</td><td align="char" char="." valign="top">30</td></tr><tr><td align="left" valign="top">Male</td><td align="char" char="." valign="top">30</td><td align="char" char="." valign="top">70</td></tr><tr><td align="left" valign="top">Transplanted organ</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Kidney</td><td align="char" char="." valign="top">24</td><td align="char" char="." valign="top">56</td></tr><tr><td align="left" valign="top">Liver</td><td align="char" char="." valign="top">4</td><td align="char" char="." valign="top">9</td></tr><tr><td align="left" valign="top">Heart and/or lung</td><td align="char" char="." valign="top">14</td><td align="char" char="." valign="top">33</td></tr><tr><td align="left" valign="top">Pancreas</td><td align="char" char="." valign="top">1</td><td align="char" char="." valign="top">2</td></tr><tr><td align="left" valign="top">Race</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Non-Hispanic White</td><td align="char" char="." valign="top">30</td><td align="char" char="." valign="top">70</td></tr><tr><td align="left" valign="top">Asian/Pacific Islander</td><td align="char" char="." valign="top">8</td><td align="char" char="." valign="top">19</td></tr><tr><td align="left" valign="top">Hispanic</td><td align="char" char="." valign="top">5</td><td align="char" char="." valign="top">12</td></tr><tr><td align="left" valign="top">Summary stage</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">In situ</td><td align="char" char="." valign="top">12</td><td align="char" char="." valign="top">28</td></tr><tr><td align="left" valign="top">Localized</td><td align="char" char="." valign="top">19</td><td align="char" char="." valign="top">46</td></tr><tr><td align="left" valign="top">Regional</td><td align="char" char="." valign="top">7</td><td align="char" char="." valign="top">14</td></tr><tr><td align="left" valign="top">Distant</td><td align="char" char="." valign="top">5</td><td align="char" char="." valign="top">12</td></tr><tr><td align="left" valign="top">Grade</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Low</td><td align="char" char="." valign="top">20</td><td align="char" char="." valign="top">47</td></tr><tr><td align="left" valign="top">High</td><td align="char" char="." valign="top">22</td><td align="char" char="." valign="top">51</td></tr><tr><td align="left" valign="top">Papillary urothelial neoplasm of low malignant potential</td><td align="char" char="." valign="top">1</td><td align="char" char="." valign="top">2</td></tr></tbody></table><table-wrap-foot><fn><p>IQR: interquartile range.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-2"><title>Detection of viruses in bladder cancers from transplant recipients</title><p>Analysis of WGS data for 38 primary tumors identified one or more virus species in 17 specimens (45%) (<xref ref-type="fig" rid="fig1">Figure 1A</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>). RNA sequencing on tumor samples for which WGS data could not be obtained revealed three additional cases containing viral sequences (45% of samples overall). Among the 20 virus-positive primary tumors, the majority harbored BKPyV (n=9) or JCPyV (n=7). High-risk HPV genotypes 16 and 51 were detected in one and two tumors, respectively. A low-risk papillomavirus, HPV28, was observed in TBC33. One BKPyV-containing tumor (case TBC05) also harbored relatively abundant amounts of HPV20. Only two reads mapped to HPV20 in the RNA dataset for case TBC05. Sequencing of metastases confirmed the presence of BKPyV in TBC06, JCPyV in TBC34, and HPV16 in TBC10. Additionally, sequencing of two separate tumor sections for TBC03 and TBC09 confirmed the presence of BKPyV in both (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Detection of viral sequences.</title><p>(<bold>A</bold>) Primary tumors. (<bold>B</bold>) Metastatic tumors. (<bold>C</bold>) Normal tissues. Viral species are shown on the rows, and each case in the cohort (represented with a TBC number) is a column. TBC numbers represent a single case and are consistent across primary, metastatic, and normal tissues. Circle size represents the breadth or fraction of the viral genome covered, and color represents the average depth of coverage of the viral k-mers with all coverages over 100 binned together. Specimens without sequencing data have a gray background.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82690-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>BK polyomavirus (BKPyV) DNA/RNA coverage plots.</title><p>Coverage plots for BKPyV DNA (gray) and RNA (red) in BKPyV-positive tumors.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82690-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>JC polyomavirus (JCPyV) DNA/RNA coverage plots.</title><p>Coverage plots for JCPyV DNA (gray) and RNA (red) in JCPyV-positive tumors.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82690-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>All human papillomavirus (HPV) DNA/RNA coverage plots.</title><p>(<bold>A-D</bold>) Coverage plots for HPV DNA (gray) and RNA (red) in HPV16 (<bold>A</bold>), HPV20 (<bold>B</bold>), HPV28 (<bold>C</bold>), and HPV51 (<bold>D</bold>) -positive tumors. Diagrams of open reading frames for each respective type are below the coverage plots. (<bold>E</bold>) Annotated assembly graph of TBC11 HPV51. (<bold>F</bold>) Details of the top human BLASTn hits from the assembly in (<bold>E</bold>). (<bold>G</bold>) 1 kb upstream and downstream of TBC11 HPV51 predicted human integration junctions with genes and repeats annotated.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82690-fig1-figsupp3-v2.tif"/></fig></fig-group><p>WGS from TBC16, TBC17, TBC18, TBC19, TBC20, TBC21, TBC22, TBC23, TBC24, TBC27 had low numbers of reads mapping to the BKPyV genome that was judged to be attributable to low levels of index-hopping from TBC01, a papillary urothelial neoplasm of low malignant potential (PUNLMP) that had extremely high BKPyV coverage and was sequenced in the same run. Considering this, along with the absence of RNA reads supporting the presence of BKPyV, we scored these tumors virus-negative.</p><p>A separate set of searches aimed at identifying divergent members of other virus groups revealed that several tumors (TBC08, TBC14, TBC25, TBC28, and TBC35) and normal tissues (TBC35, TBC28, TBC39) harbored torque teno virus (TTV) sequences from either WGS or RNA sequencing (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1c</xref>). Epstein-Barr virus was most strongly detected in one normal lymph node (TBC23) and, at low levels, in tumors TBC07 and TBC08. Considering the stronger epidemiological evidence for BKPyV and bladder cancer and its abundance in these specimens, we focused the majority of our analysis on characterizing these tumors.</p></sec><sec id="s2-3"><title>Features of BKPyV-positive tumors</title><p>BKPyV sequences detected in this study came from every genotype except IV (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). One patient with a BKPyV-positive tumor had a documented history of BKVN. BKPyV-positive tumors were found in two heart, two lung, one heart and lung, and four kidney transplant recipients. We identified unambiguous BKPyV integration sites in five of the nine BKPyV-positive tumors and in one normal tissue (<xref ref-type="fig" rid="fig2">Figure 2B</xref> &amp; <xref ref-type="table" rid="table2">Table 2</xref>). For three tumors a single integration junction was identified, and in TBC02 three junctions were identified. In the case TBC03, two separate sections from separate blocks of the primary tumor were sequenced. In 1 of the 2 sections, 11 integration junctions were identified across seven chromosomes. Only three of the junctions could be identified in the second section of the tumor, suggesting either that these junctions were not present throughout the tumor or there was insufficient tumor purity/sequencing depth to detect them.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Virus diversity and integration.</title><p>(<bold>A</bold>) Phylogenetic tree of BK polyomavirus (BKPyV) large T antigen (LTag) sequences detected in tumors (red) and reference genotypes with representative strain names. (<bold>B</bold>) Sites of BKPyV integration into host chromosomes are indicated with case numbers. Two separate sections from separate formal-fixed paraffin-embedded (FFPE) blocks of the primary tumor were sequenced for case TBC03 (samples TBC03.1 and TBC03.2). Two separate sections were also sequenced for case TBC09, but an integration site was only detected in sample TBC09.1. Integration sites were also detected in normal tissue sample TBC09N. Black and gray bars indicate cytogenetic bands; red bars indicate centromeres. (<bold>C</bold>) Coverage plot of focal amplifications adjacent to BKPyV integration sites in cases TBC03.1, TBC03.2, TBC04, and TBC08. BKPyV integration junctions are indicated by a black arrow. Colored numbers in the body of the graph indicate coverage depth.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82690-fig2-v2.tif"/></fig><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>BK polyomavirus (BKPyV) integrations sites and microhomology.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">ID</th><th align="left" valign="bottom">Human sequence match</th><th align="left" valign="bottom">Virus sequence match</th><th align="left" valign="bottom">Maximum MH length</th><th align="left" valign="bottom">MH sequence</th><th align="left" valign="bottom">Chromosome</th><th align="left" valign="bottom">Position</th><th align="left" valign="bottom">Nearest gene (Symbol)</th><th align="left" valign="bottom">Nearest gene (Ensembl ID)</th><th align="left" valign="bottom">Distance to Nearest Gene</th><th align="left" valign="bottom">Nearest RE</th><th align="left" valign="bottom">Distance to nearest RE</th></tr></thead><tbody><tr><td align="left" valign="bottom">TBC02</td><td align="left" valign="bottom">CATCATGATGATGGG</td><td align="left" valign="bottom">GATGGGCAGCCTA</td><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom">ATGGG</td><td align="left" valign="bottom">chr2</td><td align="char" char="." valign="bottom">120378301</td><td align="left" valign="bottom">INHBB</td><td align="left" valign="bottom">ENSG00000163083</td><td align="char" char="." valign="bottom">–26499</td><td align="left" valign="bottom">MIRb</td><td align="char" char="." valign="bottom">–45</td></tr><tr><td align="left" valign="bottom">TBC02</td><td align="left" valign="bottom">CTCCTGCTCATGAA</td><td align="left" valign="bottom">CATGAAGGT<break/>TAAGCATGCTA</td><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom">ATGAA</td><td align="left" valign="bottom">chr4</td><td align="char" char="." valign="bottom">145732354</td><td align="left" valign="bottom">C4orf51</td><td align="left" valign="bottom">ENSG00000237136</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">AluSq2</td><td align="char" char="." valign="bottom">–474</td></tr><tr><td align="left" valign="bottom">TBC02</td><td align="left" valign="bottom">ACCATTTAATTCCCAA</td><td align="left" valign="bottom">AGTGGAAATTAC</td><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">AC</td><td align="left" valign="bottom">chr4</td><td align="char" char="." valign="bottom">145732375</td><td align="left" valign="bottom">C4orf51</td><td align="left" valign="bottom">ENSG00000237136</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">AluSq2</td><td align="char" char="." valign="bottom">–495</td></tr><tr><td align="left" valign="bottom">TBC03.1</td><td align="left" valign="bottom">GCCTTTCTTG<break/>TGGACTGGGT</td><td align="left" valign="bottom">ATTTTCATTTCT<break/>ACTGGGGTCAGGA</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">No overlap</td><td align="left" valign="bottom">chr1</td><td align="char" char="." valign="bottom">93693546</td><td align="left" valign="bottom">BCAR3</td><td align="left" valign="bottom">ENSG00000137936</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">MIRb</td><td align="char" char="." valign="bottom">377</td></tr><tr><td align="left" valign="bottom">TBC03.1</td><td align="left" valign="bottom">TCTGTTTCT<break/>TATTTCAGAA</td><td align="left" valign="bottom">GGGTTCTCCTG<break/>TTTATAAGGTC</td><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">TC</td><td align="left" valign="bottom">chr1</td><td align="char" char="." valign="bottom">93693570</td><td align="left" valign="bottom">BCAR3</td><td align="left" valign="bottom">ENSG00000137936</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">MIRb</td><td align="char" char="." valign="bottom">353</td></tr><tr><td align="left" valign="bottom">TBC03.1</td><td align="left" valign="bottom">AGAGCCTTG<break/>GTGGTGG</td><td align="left" valign="bottom">GGTGGCAAA<break/>CAGTGCAG</td><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom">GGTGG</td><td align="left" valign="bottom">chr1</td><td align="char" char="." valign="bottom">93693890</td><td align="left" valign="bottom">BCAR3</td><td align="left" valign="bottom">ENSG00000137936</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">MIRb</td><td align="char" char="." valign="bottom">33</td></tr><tr><td align="left" valign="bottom">TBC03.1</td><td align="left" valign="bottom">GATACTTTTT<break/>AGACATGC</td><td align="left" valign="bottom">AACCATGACC<break/>TCAGGAAGGA</td><td align="char" char="." valign="bottom">4</td><td align="left" valign="bottom">CATG</td><td align="left" valign="bottom">chr1</td><td align="char" char="." valign="bottom">93694075</td><td align="left" valign="bottom">BCAR3</td><td align="left" valign="bottom">ENSG00000137936</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">MIRb</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">TBC03.1</td><td align="left" valign="bottom">CCTCAAAGC<break/>CACCCACTCC</td><td align="left" valign="bottom">TTTCCATGA<break/>GCCCCAAA</td><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom">CCAAA</td><td align="left" valign="bottom">chr1</td><td align="char" char="." valign="bottom">93694843</td><td align="left" valign="bottom">BCAR3</td><td align="left" valign="bottom">ENSG00000137936</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">MER5A</td><td align="char" char="." valign="bottom">–92</td></tr><tr><td align="left" valign="bottom">TBC03.1</td><td align="left" valign="bottom">CAATTTTTTTTTTTT</td><td align="left" valign="bottom">TTTTTTTATT<break/>TGTAAGGGTG</td><td align="char" char="." valign="bottom">7</td><td align="left" valign="bottom">TTTTTTT</td><td align="left" valign="bottom">chr12</td><td align="char" char="." valign="bottom">50449935</td><td align="left" valign="bottom">LARP4</td><td align="left" valign="bottom">ENSG00000161813</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">AluSc</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">TBC03.1</td><td align="left" valign="bottom">TGCAAGGTG<break/>CTTCATGTAT</td><td align="left" valign="bottom">AGGGGGCTTA<break/>AAGGATGCA</td><td align="char" char="." valign="bottom">4</td><td align="left" valign="bottom">TGCA</td><td align="left" valign="bottom">chr14</td><td align="char" char="." valign="bottom">95764390</td><td align="left" valign="bottom"/><td align="left" valign="bottom">ENSG00000257275</td><td align="char" char="." valign="bottom">–6735</td><td align="left" valign="bottom">MIRb</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">TBC03.1</td><td align="left" valign="bottom">TAGCCAAAA<break/>AAAAAAAGG</td><td align="left" valign="bottom">AAAAAAAAA<break/>GGCCACAG</td><td align="char" char="." valign="bottom">11</td><td align="left" valign="bottom">AAAAAAAAAGG</td><td align="left" valign="bottom">chr20</td><td align="char" char="." valign="bottom">8525269</td><td align="left" valign="bottom">PLCB1</td><td align="left" valign="bottom">ENSG00000182621</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">MamSINE1</td><td align="char" char="." valign="bottom">154</td></tr><tr><td align="left" valign="bottom">TBC03.1</td><td align="left" valign="bottom">CAATTTGGA<break/>AAACAAT</td><td align="left" valign="bottom">ATGCAAGGG<break/>CAGTGCACA</td><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">AT</td><td align="left" valign="bottom">chr3</td><td align="char" char="." valign="bottom">73059264</td><td align="left" valign="bottom">PPP4R2</td><td align="left" valign="bottom">ENSG00000163605</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">MER103C</td><td align="char" char="." valign="bottom">69</td></tr><tr><td align="left" valign="bottom">TBC03.1</td><td align="left" valign="bottom">TAAAAAGTGTCA</td><td align="left" valign="bottom">AAGTGTCAA<break/>TAGAGAAAAA</td><td align="char" char="." valign="bottom">8</td><td align="left" valign="bottom">AAGTGTCA</td><td align="left" valign="bottom">chr4</td><td align="char" char="." valign="bottom">142307350</td><td align="left" valign="bottom">INPP4B</td><td align="left" valign="bottom">ENSG00000109452</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">L2a</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">TBC03.1</td><td align="left" valign="bottom">TCACACAAT<break/>TT-TACTCCTCT</td><td align="left" valign="bottom">ACACTTTTTAC<break/>ACTCCTCTA</td><td align="char" char="." valign="bottom">8</td><td align="left" valign="bottom">ACTCCTCT</td><td align="left" valign="bottom">chr8</td><td align="char" char="." valign="bottom">140923993</td><td align="left" valign="bottom">PTK2</td><td align="left" valign="bottom">ENSG00000169398</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">L2a</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">TBC03.2</td><td align="left" valign="bottom">GTTGAGTT<break/>GGAGCA</td><td align="left" valign="bottom">CATCTAAATAA<break/>TCTCTCAAACT</td><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">CA</td><td align="left" valign="bottom">chr1</td><td align="char" char="." valign="bottom">93693160</td><td align="left" valign="bottom">BCAR3</td><td align="left" valign="bottom">ENSG00000137936</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">MER5A1</td><td align="char" char="." valign="bottom">–10</td></tr><tr><td align="left" valign="bottom">TBC03.2</td><td align="left" valign="bottom">ACCCAGTCCA<break/>CAAGAAAGGC</td><td align="left" valign="bottom">CCAGTAGAA<break/>ATGAAAAT</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">No overlap</td><td align="left" valign="bottom">chr1</td><td align="char" char="." valign="bottom">93693546</td><td align="left" valign="bottom">BCAR3</td><td align="left" valign="bottom">ENSG00000137936</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">MIRb</td><td align="char" char="." valign="bottom">377</td></tr><tr><td align="left" valign="bottom">TBC03.2</td><td align="left" valign="bottom">TCTGTTTCT<break/>TATTTCAG</td><td align="left" valign="bottom">GTTCTCCTGT<break/>TTATAAGGTC</td><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">TC</td><td align="left" valign="bottom">chr1</td><td align="char" char="." valign="bottom">93693570</td><td align="left" valign="bottom">BCAR3</td><td align="left" valign="bottom">ENSG00000137936</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">MIRb</td><td align="char" char="." valign="bottom">353</td></tr><tr><td align="left" valign="bottom">TBC04</td><td align="left" valign="bottom">GAGTGAGT<break/>TCATAG</td><td align="left" valign="bottom">CAACACTGTG<break/>GTGAG-TGAGTT</td><td align="char" char="." valign="bottom">4</td><td align="left" valign="bottom">GAGT</td><td align="left" valign="bottom">chr3</td><td align="char" char="." valign="bottom">5202593</td><td align="left" valign="bottom">EDEM1</td><td align="left" valign="bottom">ENSG00000134109</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">L2b</td><td align="char" char="." valign="bottom">–466</td></tr><tr><td align="left" valign="bottom">TBC06</td><td align="left" valign="bottom">CAGACATT<break/>-AGGA</td><td align="left" valign="bottom">TGAGGACC<break/>TAACCTGT</td><td align="char" char="." valign="bottom">4</td><td align="left" valign="bottom">AGGA</td><td align="left" valign="bottom">chr2</td><td align="char" char="." valign="bottom">201676427</td><td align="left" valign="bottom">MPP4</td><td align="left" valign="bottom">ENSG00000082126</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">MIR1_Amn</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">TBC08</td><td align="left" valign="bottom">TCCACTTT<break/>CAGTACTT</td><td align="left" valign="bottom">TGCAAAA<break/>AATCAAAT</td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">T</td><td align="left" valign="bottom">chr6</td><td align="char" char="." valign="bottom">148535326</td><td align="left" valign="bottom">SASH1</td><td align="left" valign="bottom">ENSG00000111961</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">AluSq</td><td align="char" char="." valign="bottom">995</td></tr><tr><td align="left" valign="bottom">TBC09.1</td><td align="left" valign="bottom">GGGGCGG<break/>TAACTAGAAG</td><td align="left" valign="bottom">ACTAGAAG<break/>CTTGTCGT</td><td align="char" char="." valign="bottom">8</td><td align="left" valign="bottom">ACTAGAAG</td><td align="left" valign="bottom">chr17</td><td align="char" char="." valign="bottom">61340185</td><td align="left" valign="bottom">BCAS3</td><td align="left" valign="bottom">ENSG00000141376</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">L2-3_Crp</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">TBC09N</td><td align="left" valign="bottom">GAGAAAAT<break/>AGGACTCGG</td><td align="left" valign="bottom">AAGATTCGC<break/>CTGAGAAAA</td><td align="char" char="." valign="bottom">7</td><td align="left" valign="bottom">GAGAAAA</td><td align="left" valign="bottom">chr18</td><td align="char" char="." valign="bottom">8169205</td><td align="left" valign="bottom">PTPRM</td><td align="left" valign="bottom">ENSG00000173482</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">MER127</td><td align="char" char="." valign="bottom">–648</td></tr><tr><td align="left" valign="bottom">TBC09N</td><td align="left" valign="bottom">TCCATCC<break/>TCCTCTAC</td><td align="left" valign="bottom">CTCCTCT<break/>ACATTGT</td><td align="char" char="." valign="bottom">9</td><td align="left" valign="bottom">CTCCTCTAC</td><td align="left" valign="bottom">chr3</td><td align="char" char="." valign="bottom">34028749</td><td align="left" valign="bottom">LINC01811</td><td align="left" valign="bottom">ENSG00000226320</td><td align="char" char="." valign="bottom">130585</td><td align="left" valign="bottom">L2b</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">TBC09N</td><td align="left" valign="bottom">ATGTAAT<break/>ATAAAACT</td><td align="left" valign="bottom">CATGATT<break/>TTAACCCAG</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">No overlap</td><td align="left" valign="bottom">chr3</td><td align="char" char="." valign="bottom">117678477</td><td align="left" valign="bottom"/><td align="left" valign="bottom">ENSG00000239268</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">L2c</td><td align="char" char="." valign="bottom">0</td></tr></tbody></table><table-wrap-foot><fn><p>MH: microhomology; RE: Repeat element.</p></fn></table-wrap-foot></table-wrap><p>Integration appeared consistent with a microhomology-mediated end-joining (MMEJ) model for integration, as 20 of 25 junctions (80%) had microhomology greater than or equal to 2 bp. In this model, which has previously been proposed for both HPV- and MCPyV-associated tumors (<xref ref-type="bibr" rid="bib78">Starrett et al., 2020</xref>; <xref ref-type="bibr" rid="bib75">Starrett et al., 2017</xref>; <xref ref-type="bibr" rid="bib2">Akagi et al., 2014</xref>), microhomologies between the virus and host genomes initiate DNA repair processes that can, in some cases, lead to tandem head-to-tail concatemeric repeats of the viral genome as well as focal amplifications of the flanking host chromosome. Consistent with this model, focal amplifications adjacent to BKPyV integration sites were identified in three patient tumors. In TBC03, amplification of a 17 kb region of chromosome 1 flanking a multi-copy BKPyV integrant was observed in two tumor sections (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). In TBC04, a 15 kb single-copy amplification of chromosome 3 was identified. Lastly, a 195 kb region of chromosome 6 was amplified next to the BKPyV integration junction in TBC08. Twenty-two of the identified 25 junctions (88%) intersected protein-coding genes and thus might conceivably affect gene expression or function.</p><p>BKPyV RNA and DNA abundance by sequencing generally did not correspond to specimen tumor purity or the percentage of LTag + cells (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>). Gene-level analysis of the RNA sequencing data revealed that 7 of the 9 polyomavirus-positive tumors predominantly expressed the T antigens, with little to no expression of the late genes VP1 and VP2 (encoding the major and minor capsid proteins, respectively) (<xref ref-type="fig" rid="fig3">Figure 3A and C</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). The LTag open reading frames (ORFs) in these cases were truncated before the helicase domain through deletions, frameshifts, or point mutations. The exception was the BKPyV-positive PUNLMP case TBC01, which showed a balanced expression of both early and late regions.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>BK polyomavirus (BKPyV) DNA, RNA, and large T antigen (LTag) detection in tumors.</title><p>(<bold>A</bold>) Barplots showing the abundance of BKPyV DNA and RNA reads standardized to human reads (B) Barplots of histologically estimated percent tumor purity and Immunohistochemistry (IHC)-positivity for polyomavirus LTag expression. N.D. indicates no IHC image data were generated. (C) Representative coverage plots for BKPyV DNA (gray) and RNA (red) in BKPyV-positive tumors. Relative copy numbers are indicated by colored boxes and highlight the borders of duplications and deletions in the viral genome. (D) Selected images for LTag IHC highlighting positive staining for BKPyV-positive tumors with scale bars representing 500 microns.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82690-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>BK polyomavirus (BKPyV) gene expression.</title><p>Heatmap of normalized expression (transcripts per million, TPM) of BKPyV genes per tumor.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82690-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Diagrams of the assembled BK polyomavirus (BKPyV) NCCR structures and rearrangements in tumors.</title><p><italic>P</italic>=primary tumor, M=metastatic tumor.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82690-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>T antigen immunohistochemistry (IHC) in BK polyomavirus (BKPyV)-positive tumors.</title><p>Selected images for T antigen IHC highlighting positive staining for BKPyV-positive tumors with a scale bar representing 500 microns.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82690-fig3-figsupp3-v2.tif"/></fig></fig-group><p>BKPyV isolates found in cases of polyomavirus nephropathy typically have rearrangements in the regulatory region that enhance viral replication in cell culture. However, in this study, TBC01 was the only polyomavirus-positive tumor showing evidence of regulatory region rearrangements (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>).</p><p>Immunohistochemistry (IHC) for polyomavirus LTag was performed on 18 specimens suspected to contain polyomaviruses and two negative control specimens determined to be free of detectable viral sequences. Control sections were negative for Tag staining, whereas 11 of the 18 specimens that contained polyomavirus sequences showed at least some evidence for Tag positivity (<xref ref-type="fig" rid="fig3">Figure 3B</xref> and <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>). Three tumors scored as BKPyV sequence-positive had strong to moderate LTag staining in greater than 80% of tumor cells, but the other BKPyV-positive tumors had more variable staining. Moderate to weak staining was visible in less than 0.5% of cells in the primary tumor for TBC06 (<xref ref-type="fig" rid="fig3">Figure 3D</xref>), but strong staining was observed in about 25% of cells in the metastasis. For TBC09, one sample of the tumor was &gt;90% positive for LTag staining and another sample was less than 25% positive (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>). The normal tissue for TBC09 showed BKPyV RNA and DNA coverage along a small portion of the regulatory region and small T antigen, but no staining for LTag. Although TBC01 had very high levels of BKPyV DNA and RNA reads, it had the lowest observed proportion of LTag-positive cells (&lt;1% in a section that was &gt;95% tumor as determined by cell morphology). LTag-positive cells in the TBC01 sample were almost entirely localized to the luminal margin of the tumor (<xref ref-type="fig" rid="fig3">Figure 3D</xref>).</p><p>Differential gene expression analysis for BKPyV-positive tumors versus virus-negative tumors revealed 1062 genes that were significantly differentially regulated in tumors harboring BKPyV (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1e</xref>). Clustering all primary and metastatic tumors by genes with a greater than threefold difference of expression in the above comparison, we identified three major groups that loosely correspond to the amount of BKPyV DNA and RNA in a tumor (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). A notable exception is the BKPyV-positive tumor TBC01, which falls into the cluster mostly containing virus-negative tumors.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Differential gene expression in BK polyomavirus (BKPyV)-positive tumors.</title><p>(<bold>A</bold>) Volcano plot of differential gene expression between BKPyV-positive and virus-negative tumors. Significantly differentially expressed genes (q-value &lt;0.05, DESeq2) with a fold change greater than two are in red, and genes with a fold change less than two are in pink. Non-significant genes are in gray. (<bold>B</bold>) Variance stabilized counts for APOBEC3B expression from DESeq2 grouped by normal tissues, virus-negative tumors, and BKPyV-positive tumors showing significantly increased expression in BKPyV-positive tumors (Mann-Whitney U test). TBC01 is indicated by a red dot. (<bold>C</bold>) Heatmap of Z-scores of significantly differentially expressed genes and genes relevant to bladder cancer grouped by gene ontology. High expression is red, low expression is blue. Tumors names are colored by likely etiology: BKPyV-positive, red; JC polyomavirus (JCPyV)-positive, goldenrod; HR-HPV-positive, blue; torque teno virus (TTV)-positive, green; aristolochic acid, purple; undetermined, black; multiple colors reflect multiple detected viruses or etiologies. Tumors with evidence of integration are in italics. BKPyV LTag expression is shown as log10(transcripts per million [TPM]).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82690-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>APOBEC3B germline variant and expression by BK polyomavirus (BKPyV) status.</title><p>Stabilized counts of APOBEC3B expression divided by tissue type (primary tumor, normal tissue), BKPyV status (BK), and germline variant rs1014971 status.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82690-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Host transcripts from the BK polyomavirus (BKPyV) integration site at BCAR3.</title><p>Coverage plots of DNA (gray) and RNA (red) from TBC03.1 and TBC03.2 on chromosome 1 at the BCAR3 locus.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82690-fig4-figsupp2-v2.tif"/></fig></fig-group><p>The cluster exclusively containing tumors harboring integrated BKPyV is defined by high expression of genes involved in DNA damage responses, cell cycle progression, angiogenesis, chromatin organization, mitotic spindle assembly, and chromosome condensation/separation as well as some genes associated with neuronal differentiation. Overall, these tumors have relatively low expression of keratins and genes associated with cell adhesion. Genes previously shown to be associated with cell proliferation in bladder cancer, such as <italic>FGFR3</italic>, had significantly lower expression in BKPyV-positive tumors relative to virus-negative tumors. Notably, tumors harboring BKPyV had significantly higher average <italic>APOBEC3B</italic> expression compared to both normal tissues and tumors not containing any virus (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). This observation is maintained after stratifying the cases by the germline variant, rs1014971, known to associate with increased APOBEC3B expression and bladder cancer risk with the highest average APOBEC3B expression observed in tumors with both BKPyV and two copies of rs1014971 (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>).</p><p>In TBC03, the observed BKPyV integration into <italic>BCAR3</italic> results in increased expression of the host gene. Further evaluation of RNA reads covering this region revealed a general enrichment of sense and antisense reads mapping to positions 93,688,393–93,704,476, corresponding to the amplified chromosomal region observed in the WGS dataset (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). There is an even greater enrichment of mapped reads between positions 93,694,469–93,696,857. No increases in expression in nearby host genes were observed for other cases and integration events.</p><p>Aside from integration-related copy number variants (CNVs), large-scale CNVs overall differed between BKPyV-positive and virus-negative tumors (<xref ref-type="fig" rid="fig5">Figure 5</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1g</xref>). BKPyV-positive tumors showed moderate enrichments for gains of chromosome segments 1q, 2 p, 3 p, 7q, 20q, and 22q, while losses of chromosome 2q, 6q, and 10q were also observed more frequently in BKPyV-positive tumors versus virus-negative tumors. Similar differences in copy numbers have been observed for virus-positive and virus-negative Merkel cell carcinoma (<xref ref-type="bibr" rid="bib78">Starrett et al., 2020</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Copy number variants.</title><p>Frequency plots for large copy number variants in BK polyomavirus (BKPyV)-positive tumors (panel <bold>A</bold>) and virus-negative tumors (panel <bold>C</bold>). Frequency of gains/amplifications is shown in red; losses/deletions are shown in blue. Sample level copy number variant spectra for BKPyV-positive tumors (panel <bold>B</bold>), virus-negative tumors (panel <bold>D</bold>), and all other tumors (panel <bold>E</bold>). Complete deletions are in dark blue and high copy amplifications are in red.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82690-fig5-v2.tif"/></fig></sec><sec id="s2-4"><title>Features of other virus-positive tumors</title><p>In the cases that were positive for JCPyV, DNA, and RNA coverage depth was much lower than observed for BKPyV-positive tumors, and in several DNA-positive cases, JCPyV transcription was not detected (<xref ref-type="fig" rid="fig1">Figure 1</xref>). JCPyV reads were detected in three samples from case TBC12 including the primary tumor, tumor-positive lymph node, and adjacent normal bladder wall (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). IHC detected sparse LTag staining in JCPyV-positive case TBC13, but not in any tissue samples for TBC12.</p><p>For 2 of 3 cases harboring HPV types known to cause cervical cancer (HPV16 and HPV51), transcripts encoding the E6 and E7 oncogenes were detected (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). In one HPV16+ case (TBC10), viral oncogene RNA expression was detected in both the primary and metastatic specimens. A possible HPV51 integration event in TBC11 appears to have involved simple repeat sequences and retroelements (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). Lastly, one case harbored DNA sequences aligning to HPV20 and a single case harbored DNA aligning to HPV28; however, no RNA reads were detected for these cutaneous HPV types (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>).</p><p>For the five TTV-positive tumors, the WGS analyses did not show evidence of integration. However, we were unable to assemble complete circular genomes for any of the TTVs. The missing segments all overlapped the GC-rich origin of replication that forms stable hairpins and is, therefore, relatively resistant to sequencing with standard Illumina technology (<xref ref-type="bibr" rid="bib81">Tisza et al., 2020</xref>). All observed TTV ORF1 sequences belonged to the <italic>Alphatorquevirus</italic> genus and had 51–100% amino acid identity to previously reported TTV strains (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1d</xref>).</p></sec><sec id="s2-5"><title>Mutation signature analysis</title><p>The overall tumor mutation burden, as measured by non-synonymous mutations per million bases, did not show a clear correlation with the presence of viral sequences (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). We analyzed likely somatic point mutations from all tumors and deconvoluted mutation signatures (<xref ref-type="fig" rid="fig6">Figure 6B and C</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). As expected for bladder cancer, we commonly observed single-base substitution 2 (SBS2) and SBS13 (both characteristic of APOBEC3 mutagenesis, N=13 cases) and SBS5 (associated with smoking history and <italic>ERCC2</italic> mutations, N=11 cases).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Somatic point mutations and mutation signature analysis.</title><p>(<bold>A</bold>) Tumor mutation burden (TMB, non-synonymous mutations per million bases) for each tumor in this study. Bars are colored by viral positivity (red, BK polyomavirus (BKPyV); green, TTV; blue, HR-HPV; goldenrod, JC polyomavirus (JCPyV)) or etiologic agent (aristolochic acid, purple; black, undetermined). Multiple colors reflect multiple detected viruses or etiologies. (<bold>B</bold>) Barplots of the contribution of each trinucleotide substitution for the four deconvoluted signatures with the likely mutation process indicated. (<bold>C</bold>) Proportion of each deconvoluted signature that contributes to each sample with virus status indicated by colored circles (red, BKPyV; green, TTV; blue, HR-HPV; goldenrod, JCPyV). (<bold>D</bold>) Number of unique and common trunk mutations in primary-metastatic tumor pairs and tumors with multi-region sequencing. For TBC03, TBC09, and TBC28, branches one and two refer to two separate areas of the same tumor. For TBC06 and TBC34, branches P and M refer to the primary tumor and metastasis, respectively. (<bold>E</bold>) Oncoprint for the top mutated genes in bladder cancers of transplant patients. Tumors IDs are colored by likely etiology: BKPyV-positive, red; JCPyV-positive, goldenrod; HR-HPV-positive, blue; TTV-positive, green; aristolochic acid, purple; undetermined, black. The percent of modified tumors is shown on the left and the count of the variants in each gene is represented by the barplot on the right.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82690-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Mutations signature deconvolution.</title><p>(<bold>A</bold>) Residual sum of squares and explained variance for 2–10 signatures deconvoluted by SomaticSignatures. (<bold>B</bold>) Barplot of base substitution contributions to each of the four deconvoluted signatures from SomaticSignatures. (<bold>C</bold>) Heatmap of cosine similarities of four signatures deconvoluted by Somatic Signatures versus known Single Base Substitution Signatures (SBS). (<bold>D</bold>) NMF rank survey results for 2–10 signature deconvolution by MutationalPatterns. (<bold>E</bold>) Barplot of base substitution contributions to each of the four deconvoluted signatures from MutationalPatterns. (<bold>F</bold>) Heatmap of cosine similarities of four signatures deconvoluted by MutationalPatterns versus known SBS with closest matches highlighted in red.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-82690-fig6-figsupp1-v2.tif"/></fig></fig-group><p>Four tumors (TBC16, TBC28, TBC31, TBC33) carried a predominant SBS22 signature, which is caused by the chemical aristolochic acid found in the birthwort family of plants. Cases with this signature showed a very high mutational burden (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). In support of the idea that cases with strong SBS22 signatures arose through environmental exposure, one such case, a kidney recipient, was previously diagnosed with Chinese herbal medicine nephropathy. The final deconvoluted signature closely matched the mutation spectrum caused by the deoxy-guanosine analog ganciclovir, which was recently identified in hematopoietic stem cell transplant recipients (<xref ref-type="fig" rid="fig6">Figure 6B</xref>; <xref ref-type="bibr" rid="bib23">de Kanter et al., 2021</xref>).</p></sec><sec id="s2-6"><title>Recurrent somatic mutations</title><p>First, to address the reproducibility of mutation calls in deep sequencing of FFPE samples, we analyzed the sequences from two independent sections from separate blocks for three tumors (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). Comparing the variants called in these tumors, 77–82% of inferred somatic mutations were common to both sections. Furthermore, a similar comparison showed a large percentage of variants in common between primary tumors and their metastases (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). In TBC06, 84% of the likely somatic mutations in the metastasis were found in the primary tumor, whereas only 28% of the likely somatic variants in the primary tumor were found in the metastasis. In an additional primary-metastatic pair (TBC34), we identified a similar proportion of shared ‘trunk’ mutations but the metastasis had more unique, likely somatic variants.</p><p>Numerous cellular genes were found to recurrently harbor nonsynonymous, nonsense, and frameshift mutations (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). The spectrum of frequently mutated genes is similar to those reported in various types of urothelial carcinoma (e.g. mutations in <italic>KMT2D</italic>, <italic>KDM6A,</italic> and <italic>ARID1A</italic>) (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1f</xref>; <xref ref-type="bibr" rid="bib66">Robertson et al., 2017</xref>; <xref ref-type="bibr" rid="bib56">Nassar et al., 2019</xref>; <xref ref-type="bibr" rid="bib79">Su et al., 2021</xref>). No nonsynonymous mutations were identified in <italic>FGFR3</italic> or <italic>PIK3CA,</italic> even though these genes are commonly mutated in non-muscle invasive bladder cancer (NMIBC) (<xref ref-type="bibr" rid="bib12">Cancer et al., 2014</xref>). Mutations in <italic>TP53</italic>, which are common in muscle-invasive bladder cancer (<xref ref-type="bibr" rid="bib66">Robertson et al., 2017</xref>), were detected in four tumors (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). None of the HPV-positive tumors with WGS harbored mutations in <italic>TP53</italic> or <italic>RB1</italic>. Similarly, none of the polyomavirus-positive tumors harbored mutations in <italic>RB1</italic> and only TBC08 had a frameshift mutation in <italic>TP53</italic>.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>This report presents a comprehensive molecular assessment of 43 bladder cancers arising in solid organ transplant recipients by WGS and total RNA sequencing. DNA and/or RNA sequences of human BK or JC polyomaviruses were detected in 16 tumors (37%). Expression of the polyomavirus LTag was documented immunohistochemically in 10 cases. HPV sequences were detected in six cases, including four cases with HPV types known to cause cervical cancer. Overall, this is a much higher frequency of small DNA tumor virus sequence detection compared to prior surveys of bladder cancers affecting the general population, where fewer than 5% of tumors harbor small DNA tumor virus sequences (<xref ref-type="bibr" rid="bib13">Cantalupo et al., 2018</xref>; <xref ref-type="bibr" rid="bib47">Llewellyn et al., 2018</xref>). The results suggest that human polyomaviruses and papillomaviruses can play a carcinogenic role in the development of bladder cancer, particularly among transplant recipients.</p><p>BKPyV infection in organotypic urothelial cell culture has been shown to promote cellular proliferation (<xref ref-type="bibr" rid="bib70">Schneidewind et al., 2020</xref>). This is most likely through the transforming effects of viral T antigens, as is supported here and in previous studies by the loss of late region transcripts and enrichment of early region transcription in primary tumors, and maintenance of these transcripts in metastatic lesions (<xref ref-type="bibr" rid="bib55">Müller et al., 2018</xref>). Interestingly, we observed frequent clonal loss of the p53-inactivating helicase domain of BKPyV LTag due to deletions and point mutations in the integrated virus. While such deletions in LTag are commonly observed in MCPyV-positive Merkel cell carcinoma (<xref ref-type="bibr" rid="bib72">Shuda et al., 2008</xref>), MCPyV LTag lacks the p53-inactivating activity of the C-terminal helicase domain of BKPyV. One might thus have expected the C-terminal portion of BKPyV LTag to be preserved in tumor cells. We speculate that the loss of the BKPyV helicase domain is driven by negative selection against deleterious effects of LTag on tumor survival (e.g. LTag might unwind the integrated BKPyV origin of replication and initiate ‘onion skin’ DNA structures leading to chromosomal instability and cell death). The absence of the p53-binding domain may be compensated for in some BKPyV-positive tumors through the significantly increased expression of the ubiquitin ligase TRIM71 that we observed. TRIM71 has been shown to bind and poly-ubiquitinate p53 for proteasomal degradation and prevent apoptosis during stem cell differentiation (<xref ref-type="bibr" rid="bib57">Nguyen et al., 2017</xref>).</p><p>We also observed amplification of the host genome surrounding BKPyV integration sites, consistent with circular DNA intermediates and/or MMEJ break-induced replication. Similar findings have been reported for HPV and MCPyV-associated tumors (<xref ref-type="bibr" rid="bib78">Starrett et al., 2020</xref>; <xref ref-type="bibr" rid="bib19">Czech-Sioli et al., 2020</xref>). These amplification events result in a variable number of tandem head-to-tail copies of the virus and host genome that are thought to create super-enhancers affecting viral and host gene expression (<xref ref-type="bibr" rid="bib94">Warburton et al., 2018</xref>; <xref ref-type="bibr" rid="bib28">Dooley et al., 2016</xref>). In cervical cancer, frequently only one integration event is transcriptionally active; however, in tumors carrying integrated BKPyV sequences, the abundance of viral DNA and RNA are positively correlated, suggesting that each integrated copy produces viral transcripts. While the observed integration sites in this study are unique and have not been observed in Merkel cell carcinoma, HPV16 integration has been reported previously in <italic>BCAR3</italic> (<xref ref-type="bibr" rid="bib37">Jeannot et al., 2018</xref>). Elevated expression of <italic>BCAR3</italic> has been shown to increase the proliferation, motility, and invasiveness of estrogen receptor-positive breast cancer cells after treatment with antiestrogens (<xref ref-type="bibr" rid="bib92">Wallez et al., 2014</xref>; <xref ref-type="bibr" rid="bib99">Wilson et al., 2013</xref>).</p><p>In five tumors harboring integrated BKPyV sequences (TBC02, TBC03, TBC05, TBC06, and TBC08), we observed significant upregulation of genes associated with cell cycle progression, DNA damage, histones, and the mitotic spindle. Tumors with evidence of BKPyV integration also exhibited significant downregulation of keratins and cell adhesion genes. The latter may contribute to the high-grade and invasive behavior of BKPyV-positive tumors observed in this study and others (<xref ref-type="bibr" rid="bib3">Alexiev et al., 2013</xref>; <xref ref-type="bibr" rid="bib73">Sirohi et al., 2018</xref>; <xref ref-type="bibr" rid="bib40">Kenan et al., 2015</xref>; <xref ref-type="bibr" rid="bib41">Kenan et al., 2017</xref>; <xref ref-type="bibr" rid="bib58">Nickeleit et al., 2018</xref>).</p><p>Many of the observed gene expression changes are consistent with known effects of BKPyV infection and the specific activities of LTag, which binds Rb-family proteins and alters the active pool of E2F transcription factors in the cell (<xref ref-type="bibr" rid="bib11">Caller et al., 2019</xref>; <xref ref-type="bibr" rid="bib36">Harris et al., 1996</xref>). Recent studies have shown that APOBEC3B expression is repressed by the DREAM complex (which is composed of Rb-family proteins and E2F transcription factors <xref ref-type="bibr" rid="bib76">Starrett et al., 2019</xref>) and, accordingly, we found that APOBEC3B is more highly expressed in BKPyV-positive tumors compared to normal tissues and tumors without tumor virus sequences, likely due to LTag activity. However, despite this increased expression, the mutation signature commonly attributed to APOBEC3B did not appear enriched in BKPyV-positive tumors. It is possible that tumors expressing BKPyV LTag and increased APOBEC3B manifested greater intratumor mutational heterogeneity, but we were unable to detect possible low-frequency APOBEC3-mediated variants from FFPE tissue without deeper and more accurate sequencing. Additionally, consistent with the disruption of the DREAM complex in these tumors, we observed higher expression of <italic>MYBL2</italic>, a key component of the MMB complex, and one of its targets, <italic>FOXM1</italic>, which regulates numerous genes required for G2/M progression. We also observed increased expression of <italic>FOXM1</italic> downstream targets associated with the centromere and kinetochore, which have been shown to promote improper chromosome segregation and tumorigenesis (<xref ref-type="bibr" rid="bib31">Fischer and Müller, 2017</xref>; <xref ref-type="bibr" rid="bib68">Sadasivam et al., 2012</xref>; <xref ref-type="bibr" rid="bib69">Schade et al., 2019</xref>).</p><p>BKPyV-positive tumors in our study had significantly higher expression of a number of genes that promote homologous recombination (e.g. <italic>RAD51</italic>, <italic>RAD54L</italic>, <italic>BRCA1</italic>, and <italic>BRCA2</italic>) and protect against replication fork stalling and collapse (e.g. <italic>RAD51</italic>, <italic>XRCC2</italic>, and <italic>FANCB</italic>) relative to virus-negative tumors (<xref ref-type="bibr" rid="bib85">Tye et al., 2021</xref>). Claspin (<italic>CLSPN</italic>) and <italic>TIMELESS</italic>, which interact with replicative polymerases and helicases, are also highly expressed in BKPyV-positive tumors, further promoting replication fork progression and genome stability (<xref ref-type="bibr" rid="bib7">Bianco et al., 2019</xref>). This expression pattern might promote cell survival in the face of genomic damage caused by viral genome integration, oncogene expression, and APOBEC3B upregulation.</p><p>While HPVs are not generally considered causative agents of bladder cancer, they have been detected in rare cases of bladder cancer affecting immunocompetent and immunosuppressed patients (<xref ref-type="bibr" rid="bib100">Zapatka et al., 2020</xref>; <xref ref-type="bibr" rid="bib13">Cantalupo et al., 2018</xref>; <xref ref-type="bibr" rid="bib34">Guma et al., 2016</xref>). In the current study, we identified four tumors with carcinogenic <italic>Alphapapillomavirus</italic> sequences (HPV16 or HPV51). <italic>Alphapapillomaviruses</italic> are believed to cause cancer through the sustained expression of their E6 and E7 oncoproteins, which is frequently associated with the integration of the papillomavirus genome into the tumor genome.</p><p>One case in the panel carried sequences of HPV20, a <italic>Betapapillomavirus</italic> that can cause cutaneous squamous cell carcinoma in animal model systems (<xref ref-type="bibr" rid="bib51">Michel et al., 2006</xref>). The possible involvement of <italic>Betapapillomaviruses</italic> in skin cancer in the general population remains controversial (<xref ref-type="bibr" rid="bib90">Viarisio et al., 2018</xref>). In epidermodysplasia verruciformis, a rare syndrome caused by defects in zinc-binding proteins EVER1 and EVER2, patients frequently develop non-melanoma skin cancers containing <italic>Betapapillomaviruses</italic> (<xref ref-type="bibr" rid="bib24">Dell’Oste et al., 2009</xref>). Expression of E6 and E7 from <italic>Betapapillomaviruses</italic> has been shown to promote cell survival in the face of ultraviolet radiation damage and other carcinogenic insults (<xref ref-type="bibr" rid="bib51">Michel et al., 2006</xref>; <xref ref-type="bibr" rid="bib90">Viarisio et al., 2018</xref>; <xref ref-type="bibr" rid="bib89">Viarisio et al., 2016</xref>). In the context of bladder cancer, it is possible that cutaneous papillomaviruses likewise enable the accumulation of carcinogenic DNA damage. Additionally, the identification of HPV28, an <italic>Alphapapillomavirus</italic> that is not generally associated with cervical cancer, suggests more abundant papillomavirus infections of the bladder than previously assumed, with unknown implications for carcinogenesis.</p><p>An explanation for the observation that viruses are more prevalent in bladder cancers affecting solid organ transplant recipients compared to cases in the general population is that, in combination with immune suppression, transplant recipients may often become newly infected through transmission from the donor graft at the time of transplantation, perhaps with a different viral genotype than present in the host previously. This phenomenon is commonly observed in kidney transplantation and is associated with BKVN (<xref ref-type="bibr" rid="bib74">Solis et al., 2018</xref>), but has not been documented for heart, lung, or liver transplant recipients, who are also included in the current study. Additionally, this study and one prior study (<xref ref-type="bibr" rid="bib63">Querido et al., 2020</xref>) identified JCPyV in bladder tumors. Based on the high degree of similarity between JCPyV and BKPyV, it seems reasonable to expect that the two species would behave similarly. However, the low abundance of JCPyV RNA and DNA in these specimens and the absence of integration, together with the ubiquity of latent JCPyV infections in the urinary tract, raises the possibility that these observations reflect incidental detection events.</p><p>The data from this study and others suggest that in the context of strong immune the suppression BKPyV can cause bladder cancer through clonal integration but is rarely detected in tumors of the general population. While most adults are seropositive for BKPyV, with at least 10% having detectable BKPyV in the urine, BKPyV is only observed in upwards of 4% of NMIBC cases and less than 0.25% in muscle-invasive bladder cancers in the general population (<xref ref-type="bibr" rid="bib13">Cantalupo et al., 2018</xref>; <xref ref-type="bibr" rid="bib47">Llewellyn et al., 2018</xref>). This implies that, while BKPyV LTag can provide a growth advantage to cells in culture, the large multi-domain antigen may be relatively immunogenic compared to the much smaller oncoproteins encoded by high-risk HPVs or the highly truncated MCPyV LTag isoforms typically observed in Merkel cell carcinomas. Immunologic recognition of these tumors may also be impacted by the increased expression of APOBEC3B, which can generate immunogenic neoantigens (<xref ref-type="bibr" rid="bib71">Serebrenik et al., 2019</xref>; <xref ref-type="bibr" rid="bib16">Chen et al., 2019</xref>). Several reports of regression of patients’ BKPyV-positive tumors after reduction of immune suppression support the idea that tumors constitutively expressing BKPyV gene products are readily targeted and controlled by the immune system (<xref ref-type="bibr" rid="bib50">Meier et al., 2021</xref>; <xref ref-type="bibr" rid="bib18">Cuenca et al., 2020</xref>; <xref ref-type="bibr" rid="bib32">Fu et al., 2018</xref>). The theoretical immunological costs of viral gene expression for a nascent tumor cell raise the possibility of ‘hit-and-run’ carcinogenesis. The hit-and-run hypothesis invokes the idea that a virus may play a causal role in the early stages of carcinogenesis but then become undetectable at more advanced stages of tumor development. Infection of a premalignant cell may promote its growth and survival through the expression of the viral oncogenes. Additionally, the expression of viral oncogenes may promote genome instability through the expression of the mutagenic APOBEC3 enzymes or other mechanisms that further push the cell towards transformation, as has been suggested by a recent study of BKPyV infection in differentiated urothelium (<xref ref-type="bibr" rid="bib4">Baker et al., 2022</xref>).</p><p>The heterogeneous expression of LTag observed in this study could represent transcriptional silencing or loss of BKPyV DNA from one part of the tumor, supporting the idea that tumors can lose the need for LTag expression. Alternatively, our observations could be accounted for by a multistage integration and carcinogenesis process proposed by other recent studies on BKPyV-positive urinary tumors from kidney transplant recipients (<xref ref-type="bibr" rid="bib38">Jin et al., 2021</xref>; <xref ref-type="bibr" rid="bib93">Wang et al., 2020</xref>). However, our sequencing experiments support a dominant clonally integrated form likely established early during tumor development in most BKPyV-positive tumors in this study. The only exception to this observation is TBC01, which appears to exhibit a viable BKPyV episome with a rearranged regulatory region present in a small subset of tumor cells. This tumor likely represents a passenger infection of an existing tumor (<xref ref-type="bibr" rid="bib20">Dalianis and Hirsch, 2013</xref>). Future studies should investigate the hypothesis that passenger infections might play an oncomodulatory role in tumor development. This also suggests that archetypal BKPyV, rather than the more pathogenic rearranged strains found in cases of nephropathy, is more likely to integrate and be preserved into nascent tumor cells. In support of the idea that integration may be a more common aspect of BKPyV infection than previously assumed, we identified a clonal BKPyV integrant in the normal bladder specimen from case TBC09 in both the RNA and WGS sequencing that was distinct from the BKPyV integrant observed in the tumor sample. The normal tissue integrant had multiple copies of small T antigen and a large deletion in the regulatory regions (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Only a few reads from RNA sequencing mapped to the small T antigen region, and histology of the section indicates no tumor cells or LTag staining, suggesting that the virus did not integrate into the right genomic location or maintain the needed components to drive carcinogenesis.</p><p>It remains to be seen whether TTVs contribute to disease in the context of immune suppression. A general model is that these ubiquitous viruses establish a chronic infection that the immune system generally keeps in check, but immune suppression results in increases not only in the abundance but also in the diversity of TTVs observed in hosts (<xref ref-type="bibr" rid="bib26">De Vlaminck et al., 2013</xref>). Indeed, the detection of TTVs can serve as an indicator of the degree of overall immune suppression in transplant recipients (<xref ref-type="bibr" rid="bib8">Blatter et al., 2018</xref>). Interestingly, these viruses, like papillomaviruses and polyomaviruses, also appear to be depleted for APOBEC3 target motifs, consistent with the effects of an evolutionary virus-host arms race (<xref ref-type="bibr" rid="bib62">Poulain et al., 2020</xref>; <xref ref-type="bibr" rid="bib88">Verhalen et al., 2016</xref>; <xref ref-type="bibr" rid="bib95">Warren et al., 2015a</xref>).</p><p>Until recently, this type of molecular assessment from FFPE tissues would have been nearly impossible or badly muddled by the highly damaging effects of formalin fixation and oxidation of nucleic acids over time. Recent advancements in the isolation of nucleic acids, such as low temperature and organic solvent-free deparaffinization, combined with efficient library preparation from low-concentration highly degraded sources, yielded sufficiently high-quality material for WGS variant calling and total RNA sequencing (<xref ref-type="bibr" rid="bib64">Robbe et al., 2018</xref>). To address the difficulty of accurately calling somatic variants (which can be problematic even from flash-frozen or fresh tissues), we called variants using the consensus of three modern variant callers. The lack of matched normal tissues for most cases is a limitation of this work, but our analytical approach accounted for this by focusing the analysis on mutations with &gt;10% allele frequency and those with potential functional effects, and by excluding known germline variants. Our methods were validated internally through the sequencing of separate regions from the same tumor and of primary-metastatic pairs, which reveal similar concordance of mutations as has been reported from flash-frozen tissues (<xref ref-type="bibr" rid="bib101">Zhang et al., 2014</xref>). Our variant calling approach was also validated by the observation that we detected four deconvoluted mutation signatures that match those expected from prior surveys of bladder cancer. However, the low overall coverage of our WGS remains a limitation of this study.</p><p>We identified four bladder cancers in kidney transplant recipients that exhibited abundant mutations attributable to aristolochic acid-mediated DNA adducts. Aristolochic acid is a highly nephrotoxic and mutagenic compound produced by birthwort plants, which sometimes contaminates certain types of herbal medicines and grains (<xref ref-type="bibr" rid="bib61">Poon et al., 2015</xref>). Exposure to this compound likely contributed to the patients’ need for kidney transplantation, as well as their eventual development of bladder cancer. Highlighting the highly mutagenic nature of this compound, the four cases with dominant aristolochic acid signatures were in the top seven for total mutation burden (<xref ref-type="fig" rid="fig6">Figure 6</xref>). None of the three tumors had detectable oncogenic viral sequences, but one had detectable TTV. We also identified likely ganciclovir-mediated mutations (<xref ref-type="bibr" rid="bib23">de Kanter et al., 2021</xref>) in most patients indicating that this common treatment to prevent reactivation of cytomegalovirus in solid organ transplant recipients may promote mutagenesis in the urinary bladder. Unfortunately, ganciclovir treatment history was unavailable to confirm that this is the origin of this mutation signature in these cases. Ever-decreasing sequencing costs will facilitate additional studies of this type and shed light on rare and understudied tumor types, as well as analyses of lower-grade and pre-cancerous lesions.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Sample acquisition and ethics</title><p>The Transplant Cancer Match (TCM) Study is a linkage of the US national solid organ transplant registry with multiple central cancer registries (<ext-link ext-link-type="uri" xlink:href="https://transplantmatch.cancer.gov/">https://transplantmatch.cancer.gov/</ext-link>). We used data from this linkage to identify cases of in situ or invasive bladder cancer diagnosed among transplant recipients. Staff at five participating cancer registries (California, Connecticut, Hawaii, Iowa, Kentucky) worked with hospitals in their catchment areas to retrieve archived pathology materials for selected cases.</p><p>We obtained twenty 10 micron sections from formal-fixed paraffin-embedded (FFPE) blocks for each specimen with available material. At each originating institution, the microtome blade was cleaned with nuclease-free water and ethanol between samples. Single 5 micron sections leading and trailing the twenty sections used for nucleic acid isolation were saved for histochemistry and one additional section was used for immunohistochemistry. Hematoxylin and eosin-stained sections were reviewed by a trained pathologist and tumor purity was determined by cellular morphology.</p></sec><sec id="s4-2"><title>Nucleic acid isolation</title><p>Samples were simultaneously deparaffinized and digested using 400 µL molecular-grade mineral oil (Millipore-Sigma) and 255 µL Buffer ATL (Qiagen) supplemented with 45 µL of proteinase K (Qiagen). Samples were incubated overnight at 65 °C in a shaking heat block. Samples were spun at 16,000 × g in a tabletop microcentrifuge for one minute to separate the organic and aqueous phases. Depending on the presence of visible remaining tissue, some samples were subjected to one or two additional 2 hr long digests by the addition of 25 µL of fresh proteinase K buffer. Lysates were stored at 4 °C until RNA or DNA isolation and processed within one month.</p><p>Lysates were spun at 16,000 × g in a tabletop microcentrifuge for one minute. For DNA isolation, 150 µL of supernatant was moved to a new 1.5 mL tube. 490 µL of binding buffer PM (Qiagen) and 10 µL of 3 M sodium acetate were added to the lysate. The mixture was then added to a Qiaquick spin column and spun at 16,000 × g for 30 s. Flow-through was reapplied to the spin column for complete binding. The column was washed first with 750 µL of Buffer PE (Qiagen) and then 750 µL of 80% ethanol, spinning at 16,000 × g for 30 s and discarding flow-through each time. The column was dried by spinning it at 16,000 × g for 5 min. Collection tubes were discarded, and the column was moved to a new microcentrifuge tube. 50 µL of pre-warmed, 65 °C 10% buffer EB was applied to the column and incubated for 1 min. The tube was then spun at 16,000 x g for 2 min. DNA quantity and quality were assessed by Qubit (Thermo Fisher) and spectrophotometry (DeNovix). DNA was stored at –20 °C until used for library preparation. Only samples with greater than 50 ng of DNA were processed for library prep.</p><p>For RNA isolation, 150 µL of the remaining clarified lysate was moved to a new tube. 250 µL of buffer PKD (Qiagen) was added and vortexed to mix. The remainder of the RNA extraction process was carried out using an RNeasy FFPE Kit (Qiagen) according to the manufacturer’s protocol. RNA quantity and quality were assessed by spectrophotometry (DeNovix) and TapeStation (Agilent).</p></sec><sec id="s4-3"><title>Immunohistochemistry</title><p>FFPE 5 µm thick tissue sections mounted on charged glass slides were stained with antibody against Large T Antigen, clone PAb416 (Sigma Millipore, cat. DP02), which detects LTag from multiple polyomaviruses, including SV40, BKPyV, JCPyV, WU, KI, 6, 7, 10, and 11 (<xref ref-type="bibr" rid="bib84">Toptan et al., 2016</xref>). Slides were baked in a laboratory oven at 60 °C for 1 hr prior to immunostaining on Ventana Discovery Ultra automated IHC stainer upon following conditions: CC2 (pH9) antigen retrieval for 64 min at 96 °C, antibody at concentration 0.5 µg/ml in Agilent antibody diluent (cat. S3022) for 32 min at 36 °C, Anti-Mouse HQ-Anti HQ HRP detection system for 12 min with DAB for 4 min and Hematoxylin II counterstain for 8 min. After washing per manufacturer’s instructions, slides were incubated in tap water for 10 min, dehydrated in ethanol, cleared in xylene, coverslipped with Micromount media (Leica Biosystems), and scanned on AT2 slide scanner (Leica Biosystems) for pathology review. FFPE sections of cell pellets transfected with LTag and commercial slides of SV40 infected tissue (Sigma, cat. 351 S) were used as positive controls.</p></sec><sec id="s4-4"><title>Library preparation and sequencing</title><p>50–250 ng of isolated DNA was fragmented in microtube-50 using a Covaris sonicator with the following settings: peak power: 100, duty factor: 30, cycles/burst: 1000, time: 108 s. End-repair and A-tailing were performed on fragmented DNA using the KAPA HyperPrep Kit (Roche). NEB/Illumina adaptors were ligated onto fragments with KAPA T4 DNA Ligase for 2 hr at 20 °C then treated with 4 µL USER enzyme (NEB) for 15 min at 37 °C to digest uracil-containing fragments. Ligation reactions were cleaned up using 0.8 x AMPure XP beads using the KAPA protocol. NEB dual-index oligos were added to the adaptor-ligated fragments and amplified for 6–8 cycles (depending on the amount of input fragmented DNA) using KAPA HiFi HotStart ReadyMix (Roche). Final amplified libraries were cleaned using 1 x AMPure beads with the recommended KAPA protocol. Ribosomal sequence-depleted cDNA libraries were prepared using 50 ng of total RNA with the SMARTer Stranded Total RNA-Seq Kit v2 – Pico Input Mammalian (Takara) following the manufacturer’s instructions for FFPE tissues. Final RNA and DNA libraries were assessed for size and quantity by Agilent TapeStation. Only samples that yielded libraries greater than 5 nM were sequenced.</p><p>DNA libraries were sequenced on the Illumina NovaSeq 6000 at the Center for Cancer Research (CCR) Sequencing Facility. RNA libraries were sequenced on the Illumina NovaSeq 6000 and NextSeq 550 in high output mode at the CCR Genomics Core. Sequencing metrics are reported in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>.</p></sec><sec id="s4-5"><title>Sequence alignments</title><p>Reads were trimmed using Trim Galore 0.6.0 with default settings. RNA reads was initially aligned using STAR aligner 2.5.3ab (<xref ref-type="bibr" rid="bib27">Dobin et al., 2013</xref>) against a fusion reference human genome containing hg38, all human viruses represented in RefSeq as of December 2018 (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1c</xref>), and all papillomavirus genomes from PaVE <ext-link ext-link-type="uri" xlink:href="https://pave.niaid.nih.gov">https://pave.niaid.nih.gov</ext-link> (<xref ref-type="bibr" rid="bib87">Van Doorslaer et al., 2017</xref>). Default parameters were used with the following exceptions: chimSegmentMin = 50, outFilterMultimapNmax = 1200, outFilterMismatchNmax = 30, outFilterMismatchNoverLmax = 1. Any reads that had less than 30 bp of perfect identity were excluded. Trimmed DNA reads were aligned with Bowtie2 (2.3.4.3) using the <monospace>--very-sensitive</monospace> setting to the same reference genome as mentioned above excluding RNA viruses (<xref ref-type="bibr" rid="bib44">Langmead and Salzberg, 2012</xref>). Alignments were sorted and duplicate sequences were flagged using Picard 2.20.5. Indel realignments and base quality recalculations were conducted using GATK.</p></sec><sec id="s4-6"><title>Virus detection and integration analysis</title><p>All WGS reads not mapping to the human genome were de novo assembled using MEGAHIT (1.1.4) with default parameters (<xref ref-type="bibr" rid="bib45">Li et al., 2015</xref>). All trimmed RNA reads were assembled using RNASPAdes (<xref ref-type="bibr" rid="bib10">Bushmanova et al., 2019</xref>). Assembled contigs were annotated using BLASTn and BLASTx against the NCBI nt database (October 2021) for closely related species, and CenoteTaker2 version 2.1.2 (<ext-link ext-link-type="uri" xlink:href="https://github.com/mtisza1/Cenote-Taker2">https://github.com/mtisza1/Cenote-Taker2</ext-link>; <xref ref-type="bibr" rid="bib82">Tisza, 2021</xref>) was used to identify more divergent species in contigs ≥1000 bp (<xref ref-type="bibr" rid="bib83">Tisza et al., 2021</xref>). Depth and breadth of coverage of viral species were normalized by the total number of human reads and length of the viral genome. Only species with ≥10% genome coverage and a normalized depth ≥10 for a viral genome in a given sample were considered as hits. Viral read k-mers were cross-compared against samples for uniqueness to identify index hopping or potential contamination between samples. Rearrangements in the BKPyV regulatory region were analyzed and annotated using BKTyper (<xref ref-type="bibr" rid="bib49">Martí-Carreras et al., 2020</xref>).</p><p>Bam alignments were input into Oncovirus Tools (<ext-link ext-link-type="uri" xlink:href="https://github.com/gstarrett/oncovirus_tools">https://github.com/gstarrett/oncovirus_tools</ext-link>) to call integration sites (<xref ref-type="bibr" rid="bib78">Starrett et al., 2020</xref>; <xref ref-type="bibr" rid="bib77">Starrett, 2020</xref>). It starts by extracting discordant read pairs (where one read aligns to a sequence of interest, i.e., virus, and the mated read aligns to the human genome) and any remaining reads aligned to the human genome that contain at least one 25 bp k-mer from the input sequences of interest as determined by a Bloom filter. It uses the human genomic coordinates from the above reads to identify putative integration regions by merging their stranded mapping positions to find overlaps, counting the number of reads per stranded region. Oncovirus Tools then assembles the extracted reads, together with all unaligned reads, using Spades (<xref ref-type="bibr" rid="bib5">Bankevich et al., 2012</xref>). The resulting assembly graphs are annotated with the human and viral genomes using BLASTn and the annotated assembly graphs are plotted using the R package ggraph. The output is then screened for contigs containing both human and viral hits with BLASTn e-values below 1e-10. Based on these hits, integration junctions are called and overlaps in host-virus hit on the contigs are then screened for microhomology. All putative integration sites from Oncovirus Tools were manually validated by returning to the original alignment file.</p></sec><sec id="s4-7"><title>Transcriptome clustering and differential gene expression analysis</title><p>Counts from STAR were input into R and normalized using the DESeq2 vst function (<xref ref-type="bibr" rid="bib48">Love et al., 2014</xref>). The DESeq2 model was built using the following factor: tissue type (normal, primary, metastasis), grade, stage, and virus status to evaluate their effects on gene expression. Since the RNA seq libraries were prepared in different batches on different days and in different sequencing runs, batch effects were removed using the R package limma and the function RemoveBatchEffects. These normalized counts were input into the R package ConsensusClusterPlus. Pathway analysis was conducted using Enrichr (<ext-link ext-link-type="uri" xlink:href="https://amp.pharm.mssm.edu/Enrichr">https://amp.pharm.mssm.edu/Enrichr</ext-link>) (<xref ref-type="bibr" rid="bib43">Kuleshov et al., 2016</xref>; <xref ref-type="bibr" rid="bib15">Chen et al., 2013</xref>).</p></sec><sec id="s4-8"><title>Somatic point mutation, structural variant, and copy number variant calling</title><p>Point mutations were called using Mutect2, VarScan2, and lofreq with default parameters (<xref ref-type="bibr" rid="bib42">Koboldt et al., 2012</xref>; <xref ref-type="bibr" rid="bib98">Wilm et al., 2012</xref>). Consensus calls between these variant callers were performed using SomaticSeq (3.3.0) (<xref ref-type="bibr" rid="bib29">Fang et al., 2015</xref>). Likely germline variants were annotated and removed using SnpSift and dbSNP v152. Likely somatic point mutations were further filtered by the following criteria: SomatiqSeq PASS filter, ≥10% allele frequency, ≥4 reads supporting the variant allele, and ≥8 reads of total coverage of that position. Common mutations in cancer were annotated using SnpSift and COSMIC. Somatic mutations enrichment by gene was determined using the R package dNdScv. Copy number variants in tumor WGS datasets were called using GATK4 CNV to compare them to a panel comprised of the normal-tissue WGS datasets generated in this study. Recurrent copy number variants within polyomavirus-containing tumors or tumors with no virus were determined using GISTIC2 with default parameters. Visualization and variant calling for BKPyV were performed on alignments against a BKPyV genotype Ib-2 isolate (accession number: AB369087.1).</p></sec><sec id="s4-9"><title>Mutation signature analysis</title><p>Mutation signature analysis was conducted using the likely somatic variants passing all the above criteria. Mutational Patterns and Somatic Signatures R packages were used for de novo somatic mutations signature analysis.</p></sec><sec id="s4-10"><title>Data visualization</title><p>All graphs were made in the R statistical environment (4.0.3) using the package ggplot2 or using GraphPad Prism.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>is affiliated with Leidos Biomedical Research Inc. The author has no financial interests to declare</p></fn><fn fn-type="COI-statement" id="conf3"><p>is a co-founder, shareholder, and consultant of ApoGen Biotechnologies Inc</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Validation, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Validation, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Validation, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con16"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con17"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con18"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con19"><p>Conceptualization, Resources, Supervision, Funding acquisition, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con20"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>The TCM Study is considered non-human subjects research at the National Institutes of Health because researchers do not receive identifying information on patients, and the present project utilizes materials collected previously for clinical purposes. The TCM Study was reviewed, as required, by human subjects committees at participating cancer registries.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Supporting information.</title><p>(a) Checkerboard table of samples used in this study. (b) Sequencing metrics. (c) Reference sequences used in this study. (d) Tumor torque teno virus similarities. (e) BKPyV-positive tumor vs virus-free tumor significantly differentially expressed genes. (f) Non-synonymous point mutations. (g) Copy number variants.</p></caption><media xlink:href="elife-82690-supp1-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-82690-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All refseqs for human papillomaviruses were downloaded from PaVE and refseqs for human polyomaviruses were downloaded from NCBI as of November 2018. All sequencing data generated in this study are available from dbGaP under accession phs003012.v1.p1. Viral contigs from this study are deposited in GenBank under accessions OQ469311 and OQ469312. All other contigs and larger IHC images are deposited in figshare (<ext-link ext-link-type="uri" xlink:href="https://figshare.com/projects/Common_Mechanisms_of_Virus-Mediated_Oncogenesis_in_Bladder_Cancers_Arising_in_Solid_Organ_Transplant_Recipients/132833">https://figshare.com/projects/Common_Mechanisms_of_Virus-Mediated_Oncogenesis_in_Bladder_Cancers_Arising_in_Solid_Organ_Transplant_Recipients/132833</ext-link>). Code used in this manuscript are available from <ext-link ext-link-type="uri" xlink:href="https://github.com/gstarrett/oncovirus_tools">https://github.com/gstarrett/oncovirus_tools</ext-link> (<xref ref-type="bibr" rid="bib77">Starrett, 2020</xref>).</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Starrett</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Multi-omics of Bladder Cancers of Solid Organ Transplant Recipients</data-title><source>NCBI dbGaP</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003012.v1.p1">phs003012.v1.p1</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Starrett</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>pAb416 IHC images</data-title><source>figshare</source><pub-id pub-id-type="doi">10.6084/m9.figshare.19199723.v1</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset3"><person-group person-group-type="author"><name><surname>Starrett</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Anelloviridae contigs</data-title><source>figshare</source><pub-id pub-id-type="doi">10.6084/m9.figshare.22124240.v1</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset4"><person-group person-group-type="author"><name><surname>Starrett</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Anellovirus sp. isolate TBC35T_k141_20313 ORF2/4 (ORF2/4) gene, complete cds; and ORF1 (ORF1) gene, partial cds</data-title><source>NCBI Nucleotide</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/OQ469311">OQ469311</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset5"><person-group person-group-type="author"><name><surname>Starrett</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Anellovirus sp. isolate TBC35T_k141_22964 ORF1 (ORF1) gene, partial cds; and ORF2 (ORF2) gene, complete cds</data-title><source>NCBI Nucleotide</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/OQ469312">OQ469312</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We would like to thank the CCR Genomics Core and CCR Sequencing Facility for their assistance with sequencing. This work utilized the computational resources of the NIH HPC Biowulf cluster (<ext-link ext-link-type="uri" xlink:href="http://hpc.nih.gov">http://hpc.nih.gov</ext-link>). We would also like to thank the members of the Laboratory of Cellular Oncology for their useful discussion and insights. We would like to the staff at the Scientific Registry of Transplant Recipients and participating cancer registries who assisted with the collection of the data and registry linkages.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahasan</surname><given-names>MM</given-names></name><name><surname>Wakae</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Kitamura</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Koura</surname><given-names>M</given-names></name><name><surname>Imayasu</surname><given-names>M</given-names></name><name><surname>Sakamoto</surname><given-names>N</given-names></name><name><surname>Hanaoka</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Kyo</surname><given-names>S</given-names></name><name><surname>Kondo</surname><given-names>S</given-names></name><name><surname>Fujiwara</surname><given-names>H</given-names></name><name><surname>Yoshizaki</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>S</given-names></name><name><surname>Kukimoto</surname><given-names>I</given-names></name><name><surname>Muramatsu</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Apobec3A and 3C decrease human papillomavirus 16 pseudovirion infectivity</article-title><source>Biochemical and Biophysical Research Communications</source><volume>457</volume><fpage>295</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2014.12.103</pub-id><pub-id pub-id-type="pmid">25576866</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akagi</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Broutian</surname><given-names>TR</given-names></name><name><surname>Padilla-Nash</surname><given-names>H</given-names></name><name><surname>Xiao</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>B</given-names></name><name><surname>Rocco</surname><given-names>JW</given-names></name><name><surname>Teknos</surname><given-names>TN</given-names></name><name><surname>Kumar</surname><given-names>B</given-names></name><name><surname>Wangsa</surname><given-names>D</given-names></name><name><surname>He</surname><given-names>D</given-names></name><name><surname>Ried</surname><given-names>T</given-names></name><name><surname>Symer</surname><given-names>DE</given-names></name><name><surname>Gillison</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genome-Wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability</article-title><source>Genome Research</source><volume>24</volume><fpage>185</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1101/gr.164806.113</pub-id><pub-id pub-id-type="pmid">24201445</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexiev</surname><given-names>BA</given-names></name><name><surname>Randhawa</surname><given-names>P</given-names></name><name><surname>Vazquez Martul</surname><given-names>E</given-names></name><name><surname>Zeng</surname><given-names>G</given-names></name><name><surname>Luo</surname><given-names>C</given-names></name><name><surname>Ramos</surname><given-names>E</given-names></name><name><surname>Drachenberg</surname><given-names>CB</given-names></name><name><surname>Papadimitriou</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Bk virus-associated urinary bladder carcinoma in transplant recipients: report of 2 cases, review of the literature, and proposed pathogenetic model</article-title><source>Human Pathology</source><volume>44</volume><fpage>908</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1016/j.humpath.2012.09.019</pub-id><pub-id pub-id-type="pmid">23317548</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>SC</given-names></name><name><surname>Mason</surname><given-names>AS</given-names></name><name><surname>Slip</surname><given-names>RG</given-names></name><name><surname>Skinner</surname><given-names>KT</given-names></name><name><surname>Macdonald</surname><given-names>A</given-names></name><name><surname>Masood</surname><given-names>O</given-names></name><name><surname>Harris</surname><given-names>RS</given-names></name><name><surname>Fenton</surname><given-names>TR</given-names></name><name><surname>Periyasamy</surname><given-names>M</given-names></name><name><surname>Ali</surname><given-names>S</given-names></name><name><surname>Southgate</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Induction of APOBEC3-mediated genomic damage in urothelium implicates BK polyomavirus (bkpyv) as a Hit-and-run driver for bladder cancer</article-title><source>Oncogene</source><volume>41</volume><fpage>2139</fpage><lpage>2151</lpage><pub-id pub-id-type="doi">10.1038/s41388-022-02235-8</pub-id><pub-id pub-id-type="pmid">35194151</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bankevich</surname><given-names>A</given-names></name><name><surname>Nurk</surname><given-names>S</given-names></name><name><surname>Antipov</surname><given-names>D</given-names></name><name><surname>Gurevich</surname><given-names>AA</given-names></name><name><surname>Dvorkin</surname><given-names>M</given-names></name><name><surname>Kulikov</surname><given-names>AS</given-names></name><name><surname>Lesin</surname><given-names>VM</given-names></name><name><surname>Nikolenko</surname><given-names>SI</given-names></name><name><surname>Pham</surname><given-names>S</given-names></name><name><surname>Prjibelski</surname><given-names>AD</given-names></name><name><surname>Pyshkin</surname><given-names>AV</given-names></name><name><surname>Sirotkin</surname><given-names>AV</given-names></name><name><surname>Vyahhi</surname><given-names>N</given-names></name><name><surname>Tesler</surname><given-names>G</given-names></name><name><surname>Alekseyev</surname><given-names>MA</given-names></name><name><surname>Pevzner</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing</article-title><source>Journal of Computational Biology</source><volume>19</volume><fpage>455</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1089/cmb.2012.0021</pub-id><pub-id pub-id-type="pmid">22506599</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbosa</surname><given-names>MS</given-names></name><name><surname>Edmonds</surname><given-names>C</given-names></name><name><surname>Fisher</surname><given-names>C</given-names></name><name><surname>Schiller</surname><given-names>JT</given-names></name><name><surname>Lowy</surname><given-names>DR</given-names></name><name><surname>Vousden</surname><given-names>KH</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>The region of the HPV E7 oncoprotein homologous to adenovirus E1A and SV40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation</article-title><source>The EMBO Journal</source><volume>9</volume><fpage>153</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1990.tb08091.x</pub-id><pub-id pub-id-type="pmid">2153075</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bianco</surname><given-names>JN</given-names></name><name><surname>Bergoglio</surname><given-names>V</given-names></name><name><surname>Lin</surname><given-names>Y-L</given-names></name><name><surname>Pillaire</surname><given-names>M-J</given-names></name><name><surname>Schmitz</surname><given-names>A-L</given-names></name><name><surname>Gilhodes</surname><given-names>J</given-names></name><name><surname>Lusque</surname><given-names>A</given-names></name><name><surname>Mazières</surname><given-names>J</given-names></name><name><surname>Lacroix-Triki</surname><given-names>M</given-names></name><name><surname>Roumeliotis</surname><given-names>TI</given-names></name><name><surname>Choudhary</surname><given-names>J</given-names></name><name><surname>Moreaux</surname><given-names>J</given-names></name><name><surname>Hoffmann</surname><given-names>J-S</given-names></name><name><surname>Tourrière</surname><given-names>H</given-names></name><name><surname>Pasero</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Overexpression of Claspin and timeless protects cancer cells from replication stress in a checkpoint-independent manner</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>910</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-08886-8</pub-id><pub-id pub-id-type="pmid">30796221</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blatter</surname><given-names>JA</given-names></name><name><surname>Sweet</surname><given-names>SC</given-names></name><name><surname>Conrad</surname><given-names>C</given-names></name><name><surname>Danziger-Isakov</surname><given-names>LA</given-names></name><name><surname>Faro</surname><given-names>A</given-names></name><name><surname>Goldfarb</surname><given-names>SB</given-names></name><name><surname>Hayes</surname><given-names>D</given-names></name><name><surname>Melicoff</surname><given-names>E</given-names></name><name><surname>Schecter</surname><given-names>M</given-names></name><name><surname>Storch</surname><given-names>G</given-names></name><name><surname>Visner</surname><given-names>GA</given-names></name><name><surname>Williams</surname><given-names>NM</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Anellovirus loads are associated with outcomes in pediatric lung transplantation</article-title><source>Pediatric Transplantation</source><volume>22</volume><elocation-id>13069</elocation-id><pub-id pub-id-type="doi">10.1111/petr.13069</pub-id><pub-id pub-id-type="pmid">29082660</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>MB</given-names></name><name><surname>Temiz</surname><given-names>NA</given-names></name><name><surname>Harris</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Evidence for APOBEC3B mutagenesis in multiple human cancers</article-title><source>Nature Genetics</source><volume>45</volume><fpage>977</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1038/ng.2701</pub-id><pub-id pub-id-type="pmid">23852168</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bushmanova</surname><given-names>E</given-names></name><name><surname>Antipov</surname><given-names>D</given-names></name><name><surname>Lapidus</surname><given-names>A</given-names></name><name><surname>Prjibelski</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>RnaSPAdes: a de novo transcriptome assembler and its application to RNA-Seq data</article-title><source>GigaScience</source><volume>8</volume><elocation-id>giz100</elocation-id><pub-id pub-id-type="doi">10.1093/gigascience/giz100</pub-id><pub-id pub-id-type="pmid">31494669</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caller</surname><given-names>LG</given-names></name><name><surname>Davies</surname><given-names>CTR</given-names></name><name><surname>Antrobus</surname><given-names>R</given-names></name><name><surname>Lehner</surname><given-names>PJ</given-names></name><name><surname>Weekes</surname><given-names>MP</given-names></name><name><surname>Crump</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Temporal proteomic analysis of BK polyomavirus infection reveals virus-induced g<sub>2</sub> arrest and highly effective evasion of innate immune sensing</article-title><source>Journal of Virology</source><volume>93</volume><elocation-id>e00595-19</elocation-id><pub-id pub-id-type="doi">10.1128/JVI.00595-19</pub-id><pub-id pub-id-type="pmid">31142673</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cancer</surname><given-names>T</given-names></name><name><surname>Atlas</surname><given-names>G</given-names></name><name><surname>Weinstein</surname><given-names>JN</given-names></name><name><surname>Akbani</surname><given-names>R</given-names></name><name><surname>Broom</surname><given-names>BM</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Comprehensive molecular characterization of urothelial bladder carcinoma</article-title><source>Nature</source><volume>507</volume><fpage>315</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1038/nature12965</pub-id><pub-id pub-id-type="pmid">24476821</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantalupo</surname><given-names>PG</given-names></name><name><surname>Katz</surname><given-names>JP</given-names></name><name><surname>Pipas</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Viral sequences in human cancer</article-title><source>Virology</source><volume>513</volume><fpage>208</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2017.10.017</pub-id><pub-id pub-id-type="pmid">29107929</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Cesarman</surname><given-names>E</given-names></name><name><surname>Pessin</surname><given-names>MS</given-names></name><name><surname>Lee</surname><given-names>F</given-names></name><name><surname>Culpepper</surname><given-names>J</given-names></name><name><surname>Knowles</surname><given-names>DM</given-names></name><name><surname>Moore</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma</article-title><source>Science</source><volume>266</volume><fpage>1865</fpage><lpage>1869</lpage><pub-id pub-id-type="doi">10.1126/science.7997879</pub-id><pub-id pub-id-type="pmid">7997879</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>EY</given-names></name><name><surname>Tan</surname><given-names>CM</given-names></name><name><surname>Kou</surname><given-names>Y</given-names></name><name><surname>Duan</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Meirelles</surname><given-names>GV</given-names></name><name><surname>Clark</surname><given-names>NR</given-names></name><name><surname>Ma’ayan</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool</article-title><source>BMC Bioinformatics</source><volume>14</volume><elocation-id>128</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-14-128</pub-id><pub-id pub-id-type="pmid">23586463</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Wen</surname><given-names>W</given-names></name><name><surname>Bao</surname><given-names>J</given-names></name><name><surname>Kuhs</surname><given-names>KL</given-names></name><name><surname>Cai</surname><given-names>Q</given-names></name><name><surname>Long</surname><given-names>J</given-names></name><name><surname>Shu</surname><given-names>X-O</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types</article-title><source>BMC Medical Genomics</source><volume>12</volume><elocation-id>131</elocation-id><pub-id pub-id-type="doi">10.1186/s12920-019-0579-3</pub-id><pub-id pub-id-type="pmid">31533728</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crook</surname><given-names>T</given-names></name><name><surname>Tidy</surname><given-names>JA</given-names></name><name><surname>Vousden</surname><given-names>KH</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation</article-title><source>Cell</source><volume>67</volume><fpage>547</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(91)90529-8</pub-id><pub-id pub-id-type="pmid">1657399</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuenca</surname><given-names>AG</given-names></name><name><surname>Rosales</surname><given-names>I</given-names></name><name><surname>Lee</surname><given-names>RJ</given-names></name><name><surname>Wu</surname><given-names>C-L</given-names></name><name><surname>Colvin</surname><given-names>R</given-names></name><name><surname>Feldman</surname><given-names>AS</given-names></name><name><surname>Efstathiou</surname><given-names>JA</given-names></name><name><surname>Tolkoff-Rubin</surname><given-names>N</given-names></name><name><surname>Elias</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Resolution of A high grade and metastatic BK polyomavirus-associated urothelial cell carcinoma following radical allograft nephroureterectomy and immune checkpoint treatment: A case report</article-title><source>Transplantation Proceedings</source><volume>52</volume><fpage>2720</fpage><lpage>2725</lpage><pub-id pub-id-type="doi">10.1016/j.transproceed.2020.06.012</pub-id><pub-id pub-id-type="pmid">32741665</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czech-Sioli</surname><given-names>M</given-names></name><name><surname>Günther</surname><given-names>T</given-names></name><name><surname>Therre</surname><given-names>M</given-names></name><name><surname>Spohn</surname><given-names>M</given-names></name><name><surname>Indenbirken</surname><given-names>D</given-names></name><name><surname>Theiss</surname><given-names>J</given-names></name><name><surname>Riethdorf</surname><given-names>S</given-names></name><name><surname>Qi</surname><given-names>M</given-names></name><name><surname>Alawi</surname><given-names>M</given-names></name><name><surname>Wülbeck</surname><given-names>C</given-names></name><name><surname>Fernandez-Cuesta</surname><given-names>I</given-names></name><name><surname>Esmek</surname><given-names>F</given-names></name><name><surname>Becker</surname><given-names>JC</given-names></name><name><surname>Grundhoff</surname><given-names>A</given-names></name><name><surname>Fischer</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>High-resolution analysis of merkel cell polyomavirus in merkel cell carcinoma reveals distinct integration patterns and suggests NHEJ and MMBIR as underlying mechanisms</article-title><source>PLOS Pathogens</source><volume>16</volume><elocation-id>e1008562</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008562</pub-id><pub-id pub-id-type="pmid">32833988</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalianis</surname><given-names>T</given-names></name><name><surname>Hirsch</surname><given-names>HH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Human polyomaviruses in disease and cancer</article-title><source>Virology</source><volume>437</volume><fpage>63</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2012.12.015</pub-id><pub-id pub-id-type="pmid">23357733</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Arcy</surname><given-names>ME</given-names></name><name><surname>Castenson</surname><given-names>D</given-names></name><name><surname>Lynch</surname><given-names>CF</given-names></name><name><surname>Kahn</surname><given-names>AR</given-names></name><name><surname>Morton</surname><given-names>LM</given-names></name><name><surname>Shiels</surname><given-names>MS</given-names></name><name><surname>Pfeiffer</surname><given-names>RM</given-names></name><name><surname>Engels</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Risk of rare cancers among solid organ transplant recipients</article-title><source>Journal of the National Cancer Institute</source><volume>113</volume><fpage>199</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1093/jnci/djaa078</pub-id><pub-id pub-id-type="pmid">32462187</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeCaprio</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Human papillomavirus type 16 E7 perturbs DREAM to promote cellular proliferation and mitotic gene expression</article-title><source>Oncogene</source><volume>33</volume><fpage>4036</fpage><lpage>4038</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.449</pub-id><pub-id pub-id-type="pmid">24166507</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Kanter</surname><given-names>JK</given-names></name><name><surname>Peci</surname><given-names>F</given-names></name><name><surname>Bertrums</surname><given-names>E</given-names></name><name><surname>Rosendahl Huber</surname><given-names>A</given-names></name><name><surname>van Leeuwen</surname><given-names>A</given-names></name><name><surname>van Roosmalen</surname><given-names>MJ</given-names></name><name><surname>Manders</surname><given-names>F</given-names></name><name><surname>Verheul</surname><given-names>M</given-names></name><name><surname>Oka</surname><given-names>R</given-names></name><name><surname>Brandsma</surname><given-names>AM</given-names></name><name><surname>Bierings</surname><given-names>M</given-names></name><name><surname>Belderbos</surname><given-names>M</given-names></name><name><surname>van Boxtel</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Antiviral treatment causes a unique mutational signature in cancers of transplantation recipients</article-title><source>Cell Stem Cell</source><volume>28</volume><fpage>1726</fpage><lpage>1739</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2021.07.012</pub-id><pub-id pub-id-type="pmid">34496298</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dell’Oste</surname><given-names>V</given-names></name><name><surname>Azzimonti</surname><given-names>B</given-names></name><name><surname>De Andrea</surname><given-names>M</given-names></name><name><surname>Mondini</surname><given-names>M</given-names></name><name><surname>Zavattaro</surname><given-names>E</given-names></name><name><surname>Leigheb</surname><given-names>G</given-names></name><name><surname>Weissenborn</surname><given-names>SJ</given-names></name><name><surname>Pfister</surname><given-names>H</given-names></name><name><surname>Michael</surname><given-names>KM</given-names></name><name><surname>Waterboer</surname><given-names>T</given-names></name><name><surname>Pawlita</surname><given-names>M</given-names></name><name><surname>Amantea</surname><given-names>A</given-names></name><name><surname>Landolfo</surname><given-names>S</given-names></name><name><surname>Gariglio</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>High beta-HPV DNA loads and strong seroreactivity are present in epidermodysplasia verruciformis</article-title><source>The Journal of Investigative Dermatology</source><volume>129</volume><fpage>1026</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1038/jid.2008.317</pub-id><pub-id pub-id-type="pmid">18923444</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Martel</surname><given-names>C</given-names></name><name><surname>Georges</surname><given-names>D</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Clifford</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis</article-title><source>The Lancet. Global Health</source><volume>8</volume><fpage>e180</fpage><lpage>e190</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(19)30488-7</pub-id><pub-id pub-id-type="pmid">31862245</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Vlaminck</surname><given-names>I</given-names></name><name><surname>Khush</surname><given-names>KK</given-names></name><name><surname>Strehl</surname><given-names>C</given-names></name><name><surname>Kohli</surname><given-names>B</given-names></name><name><surname>Luikart</surname><given-names>H</given-names></name><name><surname>Neff</surname><given-names>NF</given-names></name><name><surname>Okamoto</surname><given-names>J</given-names></name><name><surname>Snyder</surname><given-names>TM</given-names></name><name><surname>Cornfield</surname><given-names>DN</given-names></name><name><surname>Nicolls</surname><given-names>MR</given-names></name><name><surname>Weill</surname><given-names>D</given-names></name><name><surname>Bernstein</surname><given-names>D</given-names></name><name><surname>Valantine</surname><given-names>HA</given-names></name><name><surname>Quake</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Temporal response of the human virome to immunosuppression and antiviral therapy</article-title><source>Cell</source><volume>155</volume><fpage>1178</fpage><lpage>1187</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.10.034</pub-id><pub-id pub-id-type="pmid">24267896</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Batut</surname><given-names>P</given-names></name><name><surname>Chaisson</surname><given-names>M</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Star: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dooley</surname><given-names>KE</given-names></name><name><surname>Warburton</surname><given-names>A</given-names></name><name><surname>McBride</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tandemly integrated HPV16 can form a BRD4-dependent super-enhancer-like element that drives transcription of viral oncogenes</article-title><source>MBio</source><volume>7</volume><elocation-id>e01446-16</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.01446-16</pub-id><pub-id pub-id-type="pmid">27624132</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>LT</given-names></name><name><surname>Afshar</surname><given-names>PT</given-names></name><name><surname>Chhibber</surname><given-names>A</given-names></name><name><surname>Mohiyuddin</surname><given-names>M</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Mu</surname><given-names>JC</given-names></name><name><surname>Gibeling</surname><given-names>G</given-names></name><name><surname>Barr</surname><given-names>S</given-names></name><name><surname>Asadi</surname><given-names>NB</given-names></name><name><surname>Gerstein</surname><given-names>MB</given-names></name><name><surname>Koboldt</surname><given-names>DC</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Wong</surname><given-names>WH</given-names></name><name><surname>Lam</surname><given-names>HYK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>An ensemble approach to accurately detect somatic mutations using somaticseq</article-title><source>Genome Biology</source><volume>16</volume><elocation-id>197</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-015-0758-2</pub-id><pub-id pub-id-type="pmid">26381235</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>H</given-names></name><name><surname>Shuda</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Moore</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Clonal integration of a polyomavirus in human Merkel cell carcinoma</article-title><source>Science</source><volume>319</volume><fpage>1096</fpage><lpage>1100</lpage><pub-id pub-id-type="doi">10.1126/science.1152586</pub-id><pub-id pub-id-type="pmid">18202256</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>M</given-names></name><name><surname>Müller</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cell cycle transcription control: DREAM/muvb and Rb-E2F complexes</article-title><source>Critical Reviews in Biochemistry and Molecular Biology</source><volume>52</volume><fpage>638</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1080/10409238.2017.1360836</pub-id><pub-id pub-id-type="pmid">28799433</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>F</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Lang</surname><given-names>J</given-names></name><name><surname>Geng</surname><given-names>D</given-names></name><name><surname>Geng</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Luo</surname><given-names>M</given-names></name><name><surname>Xiong</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>C-L</given-names></name><name><surname>Miao</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Occurrence and regression of BK polyomavirus associated carcinoma: a clinical and next-generation sequencing study</article-title><source>Clinical Science</source><volume>132</volume><fpage>1753</fpage><lpage>1763</lpage><pub-id pub-id-type="doi">10.1042/CS20180443</pub-id><pub-id pub-id-type="pmid">30026258</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>SV</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The human papillomavirus replication cycle, and its links to cancer progression: a comprehensive review</article-title><source>Clinical Science</source><volume>131</volume><fpage>2201</fpage><lpage>2221</lpage><pub-id pub-id-type="doi">10.1042/CS20160786</pub-id><pub-id pub-id-type="pmid">28798073</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guma</surname><given-names>S</given-names></name><name><surname>Maglantay</surname><given-names>R</given-names></name><name><surname>Lau</surname><given-names>R</given-names></name><name><surname>Wieczorek</surname><given-names>R</given-names></name><name><surname>Melamed</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>F-M</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Makarov</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>P</given-names></name><name><surname>Pincus</surname><given-names>MR</given-names></name><name><surname>Pei</surname><given-names>Z-H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Papillary urothelial carcinoma with squamous differentiation in association with human papilloma virus: case report and literature review</article-title><source>American Journal of Clinical and Experimental Urology</source><volume>4</volume><fpage>12</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">27069958</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>G</given-names></name><name><surname>Kuppachi</surname><given-names>S</given-names></name><name><surname>Kalil</surname><given-names>RS</given-names></name><name><surname>Buck</surname><given-names>CB</given-names></name><name><surname>Lynch</surname><given-names>CF</given-names></name><name><surname>Engels</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Treatment for presumed BK polyomavirus nephropathy and risk of urinary tract cancers among kidney transplant recipients in the United States</article-title><source>American Journal of Transplantation</source><volume>18</volume><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1111/ajt.14530</pub-id><pub-id pub-id-type="pmid">28980390</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>KF</given-names></name><name><surname>Christensen</surname><given-names>JB</given-names></name><name><surname>Imperiale</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Bk virus large T antigen: interactions with the retinoblastoma family of tumor suppressor proteins and effects on cellular growth control</article-title><source>Journal of Virology</source><volume>70</volume><fpage>2378</fpage><lpage>2386</lpage><pub-id pub-id-type="doi">10.1128/JVI.70.4.2378-2386.1996</pub-id><pub-id pub-id-type="pmid">8642665</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeannot</surname><given-names>E</given-names></name><name><surname>Harlé</surname><given-names>A</given-names></name><name><surname>Holmes</surname><given-names>A</given-names></name><name><surname>Sastre-Garau</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Nuclear factor I X is a recurrent target for HPV16 insertions in anal carcinomas</article-title><source>Genes, Chromosomes &amp; Cancer</source><volume>57</volume><fpage>638</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1002/gcc.22675</pub-id><pub-id pub-id-type="pmid">30264502</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>RJ</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Elias</surname><given-names>N</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>M-H</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Guan</surname><given-names>B</given-names></name><name><surname>Geng</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Blute</surname><given-names>ML</given-names></name><name><surname>Colvin</surname><given-names>RB</given-names></name><name><surname>Wu</surname><given-names>C-L</given-names></name><name><surname>Miao</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Genome-Wide profiling of BK polyomavirus integration in bladder cancer of kidney transplant recipients reveals mechanisms of the integration at the nucleotide level</article-title><source>Oncogene</source><volume>40</volume><fpage>46</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1038/s41388-020-01502-w</pub-id><pub-id pub-id-type="pmid">33051598</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kassem</surname><given-names>A</given-names></name><name><surname>Schöpflin</surname><given-names>A</given-names></name><name><surname>Diaz</surname><given-names>C</given-names></name><name><surname>Weyers</surname><given-names>W</given-names></name><name><surname>Stickeler</surname><given-names>E</given-names></name><name><surname>Werner</surname><given-names>M</given-names></name><name><surname>Zur Hausen</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Frequent detection of Merkel cell polyomavirus in human Merkel cell carcinomas and identification of a unique deletion in the VP1 gene</article-title><source>Cancer Research</source><volume>68</volume><fpage>5009</fpage><lpage>5013</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-0949</pub-id><pub-id pub-id-type="pmid">18593898</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenan</surname><given-names>DJ</given-names></name><name><surname>Mieczkowski</surname><given-names>PA</given-names></name><name><surname>Burger-Calderon</surname><given-names>R</given-names></name><name><surname>Singh</surname><given-names>HK</given-names></name><name><surname>Nickeleit</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The oncogenic potential of BK-polyomavirus is linked to viral integration into the human genome</article-title><source>The Journal of Pathology</source><volume>237</volume><fpage>379</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1002/path.4584</pub-id><pub-id pub-id-type="pmid">26172456</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenan</surname><given-names>DJ</given-names></name><name><surname>Mieczkowski</surname><given-names>PA</given-names></name><name><surname>Latulippe</surname><given-names>E</given-names></name><name><surname>Côté</surname><given-names>I</given-names></name><name><surname>Singh</surname><given-names>HK</given-names></name><name><surname>Nickeleit</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Bk polyomavirus genomic integration and large T antigen expression: evolving paradigms in human oncogenesis</article-title><source>American Journal of Transplantation</source><volume>17</volume><fpage>1674</fpage><lpage>1680</lpage><pub-id pub-id-type="doi">10.1111/ajt.14191</pub-id><pub-id pub-id-type="pmid">28039910</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koboldt</surname><given-names>DC</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Larson</surname><given-names>DE</given-names></name><name><surname>Shen</surname><given-names>D</given-names></name><name><surname>McLellan</surname><given-names>MD</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Miller</surname><given-names>CA</given-names></name><name><surname>Mardis</surname><given-names>ER</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Wilson</surname><given-names>RK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing</article-title><source>Genome Research</source><volume>22</volume><fpage>568</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1101/gr.129684.111</pub-id><pub-id pub-id-type="pmid">22300766</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuleshov</surname><given-names>MV</given-names></name><name><surname>Jones</surname><given-names>MR</given-names></name><name><surname>Rouillard</surname><given-names>AD</given-names></name><name><surname>Fernandez</surname><given-names>NF</given-names></name><name><surname>Duan</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Koplev</surname><given-names>S</given-names></name><name><surname>Jenkins</surname><given-names>SL</given-names></name><name><surname>Jagodnik</surname><given-names>KM</given-names></name><name><surname>Lachmann</surname><given-names>A</given-names></name><name><surname>McDermott</surname><given-names>MG</given-names></name><name><surname>Monteiro</surname><given-names>CD</given-names></name><name><surname>Gundersen</surname><given-names>GW</given-names></name><name><surname>Ma’ayan</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Enrichr: a comprehensive gene set enrichment analysis web server 2016 update</article-title><source>Nucleic Acids Research</source><volume>44</volume><fpage>W90</fpage><lpage>W97</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw377</pub-id><pub-id pub-id-type="pmid">27141961</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langmead</surname><given-names>B</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fast gapped-read alignment with bowtie 2</article-title><source>Nature Methods</source><volume>9</volume><fpage>357</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1923</pub-id><pub-id pub-id-type="pmid">22388286</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>CM</given-names></name><name><surname>Luo</surname><given-names>R</given-names></name><name><surname>Sadakane</surname><given-names>K</given-names></name><name><surname>Lam</surname><given-names>TW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>MEGAHIT: an ultra-fast single-node solution for large and complex metagenomics assembly via succinct de bruijn graph</article-title><source>Bioinformatics</source><volume>31</volume><fpage>1674</fpage><lpage>1676</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btv033</pub-id><pub-id pub-id-type="pmid">25609793</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y-J</given-names></name><name><surname>Wu</surname><given-names>H-H</given-names></name><name><surname>Chen</surname><given-names>C-H</given-names></name><name><surname>Wang</surname><given-names>H-H</given-names></name><name><surname>Chiang</surname><given-names>Y-J</given-names></name><name><surname>Hsu</surname><given-names>H-H</given-names></name><name><surname>Pang</surname><given-names>S-T</given-names></name><name><surname>Wang</surname><given-names>RYL</given-names></name><name><surname>Tian</surname><given-names>Y-C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>High incidence and early onset of urinary tract cancers in patients with BK polyomavirus associated nephropathy</article-title><source>Viruses</source><volume>13</volume><elocation-id>476</elocation-id><pub-id pub-id-type="doi">10.3390/v13030476</pub-id><pub-id pub-id-type="pmid">33799453</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llewellyn</surname><given-names>MA</given-names></name><name><surname>Gordon</surname><given-names>NS</given-names></name><name><surname>Abbotts</surname><given-names>B</given-names></name><name><surname>James</surname><given-names>ND</given-names></name><name><surname>Zeegers</surname><given-names>MP</given-names></name><name><surname>Cheng</surname><given-names>KK</given-names></name><name><surname>Macdonald</surname><given-names>A</given-names></name><name><surname>Roberts</surname><given-names>S</given-names></name><name><surname>Parish</surname><given-names>JL</given-names></name><name><surname>Ward</surname><given-names>DG</given-names></name><name><surname>Bryan</surname><given-names>RT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Defining the frequency of human papillomavirus and polyomavirus infection in urothelial bladder tumours</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>11290</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-29438-y</pub-id><pub-id pub-id-type="pmid">30050097</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with deseq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martí-Carreras</surname><given-names>J</given-names></name><name><surname>Mineeva-Sangwo</surname><given-names>O</given-names></name><name><surname>Topalis</surname><given-names>D</given-names></name><name><surname>Snoeck</surname><given-names>R</given-names></name><name><surname>Andrei</surname><given-names>G</given-names></name><name><surname>Maes</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>BKTyper: free online tool for polyoma BK virus VP1 and NCCR typing</article-title><source>Viruses</source><volume>12</volume><elocation-id>837</elocation-id><pub-id pub-id-type="doi">10.3390/v12080837</pub-id><pub-id pub-id-type="pmid">32751885</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meier</surname><given-names>RPH</given-names></name><name><surname>Muller</surname><given-names>YD</given-names></name><name><surname>Dietrich</surname><given-names>P-Y</given-names></name><name><surname>Tille</surname><given-names>J-C</given-names></name><name><surname>Nikolaev</surname><given-names>S</given-names></name><name><surname>Sartori</surname><given-names>A</given-names></name><name><surname>Labidi-Galy</surname><given-names>I</given-names></name><name><surname>Ernandez</surname><given-names>T</given-names></name><name><surname>Kaur</surname><given-names>A</given-names></name><name><surname>Hirsch</surname><given-names>HH</given-names></name><name><surname>McKee</surname><given-names>TA</given-names></name><name><surname>Toso</surname><given-names>C</given-names></name><name><surname>Villard</surname><given-names>J</given-names></name><name><surname>Berney</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Immunologic clearance of a BK virus-associated metastatic renal allograft carcinoma</article-title><source>Transplantation</source><volume>105</volume><fpage>423</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1097/TP.0000000000003193</pub-id><pub-id pub-id-type="pmid">32091486</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michel</surname><given-names>A</given-names></name><name><surname>Kopp-Schneider</surname><given-names>A</given-names></name><name><surname>Zentgraf</surname><given-names>H</given-names></name><name><surname>Gruber</surname><given-names>AD</given-names></name><name><surname>de Villiers</surname><given-names>E-M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>E6/E7 expression of human papillomavirus type 20 (HPV-20) and HPV-27 influences proliferation and differentiation of the skin in UV-irradiated SKH-hr1 transgenic mice</article-title><source>Journal of Virology</source><volume>80</volume><fpage>11153</fpage><lpage>11164</lpage><pub-id pub-id-type="doi">10.1128/JVI.00954-06</pub-id><pub-id pub-id-type="pmid">16971438</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirabello</surname><given-names>L</given-names></name><name><surname>Yeager</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Clifford</surname><given-names>GM</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Cullen</surname><given-names>M</given-names></name><name><surname>Boland</surname><given-names>JF</given-names></name><name><surname>Wentzensen</surname><given-names>N</given-names></name><name><surname>Nelson</surname><given-names>CW</given-names></name><name><surname>Raine-Bennett</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Bass</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Steinberg</surname><given-names>M</given-names></name><name><surname>Burdett</surname><given-names>L</given-names></name><name><surname>Dean</surname><given-names>M</given-names></name><name><surname>Roberson</surname><given-names>D</given-names></name><name><surname>Mitchell</surname><given-names>J</given-names></name><name><surname>Lorey</surname><given-names>T</given-names></name><name><surname>Franceschi</surname><given-names>S</given-names></name><name><surname>Castle</surname><given-names>PE</given-names></name><name><surname>Walker</surname><given-names>J</given-names></name><name><surname>Zuna</surname><given-names>R</given-names></name><name><surname>Kreimer</surname><given-names>AR</given-names></name><name><surname>Beachler</surname><given-names>DC</given-names></name><name><surname>Hildesheim</surname><given-names>A</given-names></name><name><surname>Gonzalez</surname><given-names>P</given-names></name><name><surname>Porras</surname><given-names>C</given-names></name><name><surname>Burk</surname><given-names>RD</given-names></name><name><surname>Schiffman</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Hpv16 E7 genetic conservation is critical to carcinogenesis</article-title><source>Cell</source><volume>170</volume><fpage>1164</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.08.001</pub-id><pub-id pub-id-type="pmid">28886384</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moens</surname><given-names>U</given-names></name><name><surname>Macdonald</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Effect of the large and small T-antigens of human polyomaviruses on signaling pathways</article-title><source>International Journal of Molecular Sciences</source><volume>20</volume><elocation-id>3914</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20163914</pub-id><pub-id pub-id-type="pmid">31408949</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>S</given-names></name><name><surname>Takeuchi</surname><given-names>T</given-names></name><name><surname>Ishii</surname><given-names>Y</given-names></name><name><surname>Yugawa</surname><given-names>T</given-names></name><name><surname>Kiyono</surname><given-names>T</given-names></name><name><surname>Nishina</surname><given-names>H</given-names></name><name><surname>Kukimoto</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Human papillomavirus 16 E6 upregulates APOBEC3B via the TeaD transcription factor</article-title><source>Journal of Virology</source><volume>91</volume><elocation-id>e02413-16</elocation-id><pub-id pub-id-type="doi">10.1128/JVI.02413-16</pub-id><pub-id pub-id-type="pmid">28077648</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>DC</given-names></name><name><surname>Rämö</surname><given-names>M</given-names></name><name><surname>Naegele</surname><given-names>K</given-names></name><name><surname>Ribi</surname><given-names>S</given-names></name><name><surname>Wetterauer</surname><given-names>C</given-names></name><name><surname>Perrina</surname><given-names>V</given-names></name><name><surname>Quagliata</surname><given-names>L</given-names></name><name><surname>Vlajnic</surname><given-names>T</given-names></name><name><surname>Ruiz</surname><given-names>C</given-names></name><name><surname>Balitzki</surname><given-names>B</given-names></name><name><surname>Grobholz</surname><given-names>R</given-names></name><name><surname>Gosert</surname><given-names>R</given-names></name><name><surname>Ajuh</surname><given-names>ET</given-names></name><name><surname>Hirsch</surname><given-names>HH</given-names></name><name><surname>Bubendorf</surname><given-names>L</given-names></name><name><surname>Rentsch</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Donor-Derived, metastatic urothelial cancer after kidney transplantation associated with a potentially oncogenic BK polyomavirus</article-title><source>The Journal of Pathology</source><volume>244</volume><fpage>265</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1002/path.5012</pub-id><pub-id pub-id-type="pmid">29205775</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nassar</surname><given-names>AH</given-names></name><name><surname>Umeton</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Lundgren</surname><given-names>K</given-names></name><name><surname>Harshman</surname><given-names>L</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Preston</surname><given-names>M</given-names></name><name><surname>Dong</surname><given-names>F</given-names></name><name><surname>Bellmunt</surname><given-names>J</given-names></name><name><surname>Mouw</surname><given-names>KW</given-names></name><name><surname>Choueiri</surname><given-names>TK</given-names></name><name><surname>Sonpavde</surname><given-names>G</given-names></name><name><surname>Kwiatkowski</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites</article-title><source>Clinical Cancer Research</source><volume>25</volume><fpage>2458</fpage><lpage>2470</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-3147</pub-id><pub-id pub-id-type="pmid">30593515</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>DTT</given-names></name><name><surname>Richter</surname><given-names>D</given-names></name><name><surname>Michel</surname><given-names>G</given-names></name><name><surname>Mitschka</surname><given-names>S</given-names></name><name><surname>Kolanus</surname><given-names>W</given-names></name><name><surname>Cuevas</surname><given-names>E</given-names></name><name><surname>Wulczyn</surname><given-names>FG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The ubiquitin ligase LIN41/TRIM71 targets p53 to antagonize cell death and differentiation pathways during stem cell differentiation</article-title><source>Cell Death and Differentiation</source><volume>24</volume><fpage>1063</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.1038/cdd.2017.54</pub-id><pub-id pub-id-type="pmid">28430184</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nickeleit</surname><given-names>V</given-names></name><name><surname>Singh</surname><given-names>HK</given-names></name><name><surname>Kenan</surname><given-names>DJ</given-names></name><name><surname>Mieczkowski</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The two-faced nature of BK polyomavirus: lytic infection or non-lytic large-T-positive carcinoma</article-title><source>The Journal of Pathology</source><volume>246</volume><fpage>7</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1002/path.5127</pub-id><pub-id pub-id-type="pmid">29931826</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papadimitriou</surname><given-names>JC</given-names></name><name><surname>Randhawa</surname><given-names>P</given-names></name><name><surname>Rinaldo</surname><given-names>CH</given-names></name><name><surname>Drachenberg</surname><given-names>CB</given-names></name><name><surname>Alexiev</surname><given-names>B</given-names></name><name><surname>Hirsch</surname><given-names>HH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Bk polyomavirus infection and renourinary tumorigenesis</article-title><source>American Journal of Transplantation</source><volume>16</volume><fpage>398</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1111/ajt.13550</pub-id><pub-id pub-id-type="pmid">26731714</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peretti</surname><given-names>A</given-names></name><name><surname>Geoghegan</surname><given-names>EM</given-names></name><name><surname>Pastrana</surname><given-names>DV</given-names></name><name><surname>Smola</surname><given-names>S</given-names></name><name><surname>Feld</surname><given-names>P</given-names></name><name><surname>Sauter</surname><given-names>M</given-names></name><name><surname>Lohse</surname><given-names>S</given-names></name><name><surname>Ramesh</surname><given-names>M</given-names></name><name><surname>Lim</surname><given-names>ES</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Borgogna</surname><given-names>C</given-names></name><name><surname>FitzGerald</surname><given-names>PC</given-names></name><name><surname>Bliskovsky</surname><given-names>V</given-names></name><name><surname>Starrett</surname><given-names>GJ</given-names></name><name><surname>Law</surname><given-names>EK</given-names></name><name><surname>Harris</surname><given-names>RS</given-names></name><name><surname>Killian</surname><given-names>JK</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Pineda</surname><given-names>M</given-names></name><name><surname>Meltzer</surname><given-names>PS</given-names></name><name><surname>Boldorini</surname><given-names>R</given-names></name><name><surname>Gariglio</surname><given-names>M</given-names></name><name><surname>Buck</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Characterization of BK polyomaviruses from kidney transplant recipients suggests a role for APOBEC3 in driving in-host virus evolution</article-title><source>Cell Host &amp; Microbe</source><volume>23</volume><fpage>628</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2018.04.005</pub-id><pub-id pub-id-type="pmid">29746834</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poon</surname><given-names>SL</given-names></name><name><surname>Huang</surname><given-names>MN</given-names></name><name><surname>Choo</surname><given-names>Y</given-names></name><name><surname>McPherson</surname><given-names>JR</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Heng</surname><given-names>HL</given-names></name><name><surname>Gan</surname><given-names>A</given-names></name><name><surname>Myint</surname><given-names>SS</given-names></name><name><surname>Siew</surname><given-names>EY</given-names></name><name><surname>Ler</surname><given-names>LD</given-names></name><name><surname>Ng</surname><given-names>LG</given-names></name><name><surname>Weng</surname><given-names>W-H</given-names></name><name><surname>Chuang</surname><given-names>C-K</given-names></name><name><surname>Yuen</surname><given-names>JS</given-names></name><name><surname>Pang</surname><given-names>S-T</given-names></name><name><surname>Tan</surname><given-names>P</given-names></name><name><surname>Teh</surname><given-names>BT</given-names></name><name><surname>Rozen</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mutation signatures implicate aristolochic acid in bladder cancer development</article-title><source>Genome Medicine</source><volume>7</volume><elocation-id>38</elocation-id><pub-id pub-id-type="doi">10.1186/s13073-015-0161-3</pub-id><pub-id pub-id-type="pmid">26015808</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulain</surname><given-names>F</given-names></name><name><surname>Lejeune</surname><given-names>N</given-names></name><name><surname>Willemart</surname><given-names>K</given-names></name><name><surname>Gillet</surname><given-names>NA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Footprint of the host restriction factors APOBEC3 on the genome of human viruses</article-title><source>PLOS Pathogens</source><volume>16</volume><elocation-id>e1008718</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008718</pub-id><pub-id pub-id-type="pmid">32797103</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Querido</surname><given-names>S</given-names></name><name><surname>Fernandes</surname><given-names>I</given-names></name><name><surname>Weigert</surname><given-names>A</given-names></name><name><surname>Casimiro</surname><given-names>S</given-names></name><name><surname>Albuquerque</surname><given-names>C</given-names></name><name><surname>Ramos</surname><given-names>S</given-names></name><name><surname>Adragão</surname><given-names>T</given-names></name><name><surname>Luz</surname><given-names>I</given-names></name><name><surname>Paixão</surname><given-names>P</given-names></name><name><surname>Chasqueira</surname><given-names>M</given-names></name><name><surname>Santos</surname><given-names>M</given-names></name><name><surname>Machado</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>High-grade urothelial carcinoma in a kidney transplant recipient after JC virus nephropathy: the first evidence of JC virus as a potential oncovirus in bladder cancer</article-title><source>American Journal of Transplantation</source><volume>20</volume><fpage>1188</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.1111/ajt.15663</pub-id><pub-id pub-id-type="pmid">31654479</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robbe</surname><given-names>P</given-names></name><name><surname>Popitsch</surname><given-names>N</given-names></name><name><surname>Knight</surname><given-names>SJL</given-names></name><name><surname>Antoniou</surname><given-names>P</given-names></name><name><surname>Becq</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>M</given-names></name><name><surname>Kanapin</surname><given-names>A</given-names></name><name><surname>Samsonova</surname><given-names>A</given-names></name><name><surname>Vavoulis</surname><given-names>DV</given-names></name><name><surname>Ross</surname><given-names>MT</given-names></name><name><surname>Kingsbury</surname><given-names>Z</given-names></name><name><surname>Cabes</surname><given-names>M</given-names></name><name><surname>Ramos</surname><given-names>SDC</given-names></name><name><surname>Page</surname><given-names>S</given-names></name><name><surname>Dreau</surname><given-names>H</given-names></name><name><surname>Ridout</surname><given-names>K</given-names></name><name><surname>Jones</surname><given-names>LJ</given-names></name><name><surname>Tuff-Lacey</surname><given-names>A</given-names></name><name><surname>Henderson</surname><given-names>S</given-names></name><name><surname>Mason</surname><given-names>J</given-names></name><name><surname>Buffa</surname><given-names>FM</given-names></name><name><surname>Verrill</surname><given-names>C</given-names></name><name><surname>Maldonado-Perez</surname><given-names>D</given-names></name><name><surname>Roxanis</surname><given-names>I</given-names></name><name><surname>Collantes</surname><given-names>E</given-names></name><name><surname>Browning</surname><given-names>L</given-names></name><name><surname>Dhar</surname><given-names>S</given-names></name><name><surname>Damato</surname><given-names>S</given-names></name><name><surname>Davies</surname><given-names>S</given-names></name><name><surname>Caulfield</surname><given-names>M</given-names></name><name><surname>Bentley</surname><given-names>DR</given-names></name><name><surname>Taylor</surname><given-names>JC</given-names></name><name><surname>Turnbull</surname><given-names>C</given-names></name><name><surname>Schuh</surname><given-names>A</given-names></name><collab>100,000 Genomes Project</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Clinical whole-genome sequencing from routine formalin-fixed, paraffin-embedded specimens: pilot study for the 100,000 genomes project</article-title><source>Genetics in Medicine</source><volume>20</volume><fpage>1196</fpage><lpage>1205</lpage><pub-id pub-id-type="doi">10.1038/gim.2017.241</pub-id><pub-id pub-id-type="pmid">29388947</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>SA</given-names></name><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Klimczak</surname><given-names>LJ</given-names></name><name><surname>Grimm</surname><given-names>SA</given-names></name><name><surname>Fargo</surname><given-names>D</given-names></name><name><surname>Stojanov</surname><given-names>P</given-names></name><name><surname>Kiezun</surname><given-names>A</given-names></name><name><surname>Kryukov</surname><given-names>GV</given-names></name><name><surname>Carter</surname><given-names>SL</given-names></name><name><surname>Saksena</surname><given-names>G</given-names></name><name><surname>Harris</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>RR</given-names></name><name><surname>Resnick</surname><given-names>MA</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Gordenin</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers</article-title><source>Nature Genetics</source><volume>45</volume><fpage>970</fpage><lpage>976</lpage><pub-id pub-id-type="doi">10.1038/ng.2702</pub-id><pub-id pub-id-type="pmid">23852170</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>AG</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Al-Ahmadie</surname><given-names>H</given-names></name><name><surname>Bellmunt</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>G</given-names></name><name><surname>Cherniack</surname><given-names>AD</given-names></name><name><surname>Hinoue</surname><given-names>T</given-names></name><name><surname>Laird</surname><given-names>PW</given-names></name><name><surname>Hoadley</surname><given-names>KA</given-names></name><name><surname>Akbani</surname><given-names>R</given-names></name><name><surname>Castro</surname><given-names>MAA</given-names></name><name><surname>Gibb</surname><given-names>EA</given-names></name><name><surname>Kanchi</surname><given-names>RS</given-names></name><name><surname>Gordenin</surname><given-names>DA</given-names></name><name><surname>Shukla</surname><given-names>SA</given-names></name><name><surname>Sanchez-Vega</surname><given-names>F</given-names></name><name><surname>Hansel</surname><given-names>DE</given-names></name><name><surname>Czerniak</surname><given-names>BA</given-names></name><name><surname>Reuter</surname><given-names>VE</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><name><surname>de Sa Carvalho</surname><given-names>B</given-names></name><name><surname>Chagas</surname><given-names>VS</given-names></name><name><surname>Mungall</surname><given-names>KL</given-names></name><name><surname>Sadeghi</surname><given-names>S</given-names></name><name><surname>Pedamallu</surname><given-names>CS</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Klimczak</surname><given-names>LJ</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Choo</surname><given-names>C</given-names></name><name><surname>Ojesina</surname><given-names>AI</given-names></name><name><surname>Bullman</surname><given-names>S</given-names></name><name><surname>Leraas</surname><given-names>KM</given-names></name><name><surname>Lichtenberg</surname><given-names>TM</given-names></name><name><surname>Wu</surname><given-names>CJ</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>McConkey</surname><given-names>DJ</given-names></name><collab>TCGA Research Network</collab><name><surname>Weinstein</surname><given-names>JN</given-names></name><name><surname>Kwiatkowski</surname><given-names>DJ</given-names></name><name><surname>Lerner</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Comprehensive molecular characterization of muscle-invasive bladder cancer</article-title><source>Cell</source><volume>171</volume><fpage>540</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.09.007</pub-id><pub-id pub-id-type="pmid">28988769</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosty</surname><given-names>C</given-names></name><name><surname>Sheffer</surname><given-names>M</given-names></name><name><surname>Tsafrir</surname><given-names>D</given-names></name><name><surname>Stransky</surname><given-names>N</given-names></name><name><surname>Tsafrir</surname><given-names>I</given-names></name><name><surname>Peter</surname><given-names>M</given-names></name><name><surname>de Crémoux</surname><given-names>P</given-names></name><name><surname>de La Rochefordière</surname><given-names>A</given-names></name><name><surname>Salmon</surname><given-names>R</given-names></name><name><surname>Dorval</surname><given-names>T</given-names></name><name><surname>Thiery</surname><given-names>JP</given-names></name><name><surname>Couturier</surname><given-names>J</given-names></name><name><surname>Radvanyi</surname><given-names>F</given-names></name><name><surname>Domany</surname><given-names>E</given-names></name><name><surname>Sastre-Garau</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma</article-title><source>Oncogene</source><volume>24</volume><fpage>7094</fpage><lpage>7104</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1208854</pub-id><pub-id pub-id-type="pmid">16007141</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadasivam</surname><given-names>S</given-names></name><name><surname>Duan</surname><given-names>S</given-names></name><name><surname>DeCaprio</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The muvb complex sequentially recruits B-Myb and FoxM1 to promote mitotic gene expression</article-title><source>Genes &amp; Development</source><volume>26</volume><fpage>474</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1101/gad.181933.111</pub-id><pub-id pub-id-type="pmid">22391450</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schade</surname><given-names>AE</given-names></name><name><surname>Oser</surname><given-names>MG</given-names></name><name><surname>Nicholson</surname><given-names>HE</given-names></name><name><surname>DeCaprio</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cyclin D-Cdk4 relieves cooperative repression of proliferation and cell cycle gene expression by DREAM and Rb</article-title><source>Oncogene</source><volume>38</volume><fpage>4962</fpage><lpage>4976</lpage><pub-id pub-id-type="doi">10.1038/s41388-019-0767-9</pub-id><pub-id pub-id-type="pmid">30833638</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneidewind</surname><given-names>L</given-names></name><name><surname>Neumann</surname><given-names>T</given-names></name><name><surname>Plis</surname><given-names>A</given-names></name><name><surname>Brückmann</surname><given-names>S</given-names></name><name><surname>Keiser</surname><given-names>M</given-names></name><name><surname>Krüger</surname><given-names>W</given-names></name><name><surname>Schmidt</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Novel 3D organotypic urothelial cell culture model for identification of new therapeutic approaches in urological infections</article-title><source>Journal of Clinical Virology</source><volume>124</volume><elocation-id>104283</elocation-id><pub-id pub-id-type="doi">10.1016/j.jcv.2020.104283</pub-id><pub-id pub-id-type="pmid">31986366</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serebrenik</surname><given-names>AA</given-names></name><name><surname>Starrett</surname><given-names>GJ</given-names></name><name><surname>Leenen</surname><given-names>S</given-names></name><name><surname>Jarvis</surname><given-names>MC</given-names></name><name><surname>Shaban</surname><given-names>NM</given-names></name><name><surname>Salamango</surname><given-names>DJ</given-names></name><name><surname>Nilsen</surname><given-names>H</given-names></name><name><surname>Brown</surname><given-names>WL</given-names></name><name><surname>Harris</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The deaminase APOBEC3B triggers the death of cells lacking uracil DNA glycosylase</article-title><source>PNAS</source><volume>116</volume><fpage>22158</fpage><lpage>22163</lpage><pub-id pub-id-type="doi">10.1073/pnas.1904024116</pub-id><pub-id pub-id-type="pmid">31611371</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shuda</surname><given-names>M</given-names></name><name><surname>Feng</surname><given-names>H</given-names></name><name><surname>Kwun</surname><given-names>HJ</given-names></name><name><surname>Rosen</surname><given-names>ST</given-names></name><name><surname>Gjoerup</surname><given-names>O</given-names></name><name><surname>Moore</surname><given-names>PS</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>T antigen mutations are a human tumor-specific signature for merkel cell polyomavirus</article-title><source>PNAS</source><volume>105</volume><fpage>16272</fpage><lpage>16277</lpage><pub-id pub-id-type="doi">10.1073/pnas.0806526105</pub-id><pub-id pub-id-type="pmid">18812503</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sirohi</surname><given-names>D</given-names></name><name><surname>Vaske</surname><given-names>C</given-names></name><name><surname>Sanborn</surname><given-names>Z</given-names></name><name><surname>Smith</surname><given-names>SC</given-names></name><name><surname>Don</surname><given-names>MD</given-names></name><name><surname>Lindsey</surname><given-names>KG</given-names></name><name><surname>Federman</surname><given-names>S</given-names></name><name><surname>Vankalakunti</surname><given-names>M</given-names></name><name><surname>Koo</surname><given-names>J</given-names></name><name><surname>Bose</surname><given-names>S</given-names></name><name><surname>Peralta-Venturina</surname><given-names>M de</given-names></name><name><surname>Ziffle</surname><given-names>J</given-names></name><name><surname>Grenert</surname><given-names>JP</given-names></name><name><surname>Miller</surname><given-names>S</given-names></name><name><surname>Chiu</surname><given-names>C</given-names></name><name><surname>Amin</surname><given-names>MB</given-names></name><name><surname>Simko</surname><given-names>JP</given-names></name><name><surname>Stohr</surname><given-names>BA</given-names></name><name><surname>Luthringer</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Polyoma virus-associated carcinomas of the urologic tract: a clinicopathologic and molecular study</article-title><source>Modern Pathology</source><volume>31</volume><fpage>1429</fpage><lpage>1441</lpage><pub-id pub-id-type="doi">10.1038/s41379-018-0065-z</pub-id><pub-id pub-id-type="pmid">29765141</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solis</surname><given-names>M</given-names></name><name><surname>Velay</surname><given-names>A</given-names></name><name><surname>Porcher</surname><given-names>R</given-names></name><name><surname>Domingo-Calap</surname><given-names>P</given-names></name><name><surname>Soulier</surname><given-names>E</given-names></name><name><surname>Joly</surname><given-names>M</given-names></name><name><surname>Meddeb</surname><given-names>M</given-names></name><name><surname>Kack-Kack</surname><given-names>W</given-names></name><name><surname>Moulin</surname><given-names>B</given-names></name><name><surname>Bahram</surname><given-names>S</given-names></name><name><surname>Stoll-Keller</surname><given-names>F</given-names></name><name><surname>Barth</surname><given-names>H</given-names></name><name><surname>Caillard</surname><given-names>S</given-names></name><name><surname>Fafi-Kremer</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Neutralizing antibody-mediated response and risk of BK virus-associated nephropathy</article-title><source>Journal of the American Society of Nephrology</source><volume>29</volume><fpage>326</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1681/ASN.2017050532</pub-id><pub-id pub-id-type="pmid">29042457</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starrett</surname><given-names>GJ</given-names></name><name><surname>Marcelus</surname><given-names>C</given-names></name><name><surname>Cantalupo</surname><given-names>PG</given-names></name><name><surname>Katz</surname><given-names>JP</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Akagi</surname><given-names>K</given-names></name><name><surname>Thakuria</surname><given-names>M</given-names></name><name><surname>Rabinowits</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>LC</given-names></name><name><surname>Symer</surname><given-names>DE</given-names></name><name><surname>Pipas</surname><given-names>JM</given-names></name><name><surname>Harris</surname><given-names>RS</given-names></name><name><surname>DeCaprio</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Merkel cell polyomavirus exhibits dominant control of the tumor genome and transcriptome in virus-associated Merkel cell carcinoma</article-title><source>MBio</source><volume>8</volume><elocation-id>e02079-16</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.02079-16</pub-id><pub-id pub-id-type="pmid">28049147</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starrett</surname><given-names>GJ</given-names></name><name><surname>Serebrenik</surname><given-names>AA</given-names></name><name><surname>Roelofs</surname><given-names>PA</given-names></name><name><surname>McCann</surname><given-names>JL</given-names></name><name><surname>Verhalen</surname><given-names>B</given-names></name><name><surname>Jarvis</surname><given-names>MC</given-names></name><name><surname>Stewart</surname><given-names>TA</given-names></name><name><surname>Law</surname><given-names>EK</given-names></name><name><surname>Krupp</surname><given-names>A</given-names></name><name><surname>Jiang</surname><given-names>M</given-names></name><name><surname>Martens</surname><given-names>JWM</given-names></name><name><surname>Cahir-McFarland</surname><given-names>E</given-names></name><name><surname>Span</surname><given-names>PN</given-names></name><name><surname>Harris</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Polyomavirus T antigen induces APOBEC3B expression using an LXCXE-dependent and TP53-independent mechanism</article-title><source>MBio</source><volume>10</volume><elocation-id>e02690-18</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.02690-18</pub-id><pub-id pub-id-type="pmid">30723127</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Starrett</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Oncovirus tools</data-title><version designator="99c8707">99c8707</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/gstarrett/oncovirus_tools">https://github.com/gstarrett/oncovirus_tools</ext-link></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starrett</surname><given-names>GJ</given-names></name><name><surname>Thakuria</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Marcelus</surname><given-names>C</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Nomburg</surname><given-names>J</given-names></name><name><surname>Thorner</surname><given-names>AR</given-names></name><name><surname>Slevin</surname><given-names>MK</given-names></name><name><surname>Powers</surname><given-names>W</given-names></name><name><surname>Burns</surname><given-names>RT</given-names></name><name><surname>Perry</surname><given-names>C</given-names></name><name><surname>Piris</surname><given-names>A</given-names></name><name><surname>Kuo</surname><given-names>FC</given-names></name><name><surname>Rabinowits</surname><given-names>G</given-names></name><name><surname>Giobbie-Hurder</surname><given-names>A</given-names></name><name><surname>MacConaill</surname><given-names>LE</given-names></name><name><surname>DeCaprio</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical and molecular characterization of virus-positive and virus-negative Merkel cell carcinoma</article-title><source>Genome Medicine</source><volume>12</volume><elocation-id>30</elocation-id><pub-id pub-id-type="doi">10.1186/s13073-020-00727-4</pub-id><pub-id pub-id-type="pmid">32188490</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Bazai</surname><given-names>SK</given-names></name><name><surname>Compérat</surname><given-names>E</given-names></name><name><surname>Mouawad</surname><given-names>R</given-names></name><name><surname>Yao</surname><given-names>H</given-names></name><name><surname>Rouprêt</surname><given-names>M</given-names></name><name><surname>Spano</surname><given-names>J-P</given-names></name><name><surname>Khayat</surname><given-names>D</given-names></name><name><surname>Davidson</surname><given-names>I</given-names></name><name><surname>Tannir</surname><given-names>NN</given-names></name><name><surname>Yan</surname><given-names>F</given-names></name><name><surname>Malouf</surname><given-names>GG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Comprehensive integrative profiling of upper tract urothelial carcinomas</article-title><source>Genome Biology</source><volume>22</volume><elocation-id>7</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-020-02230-w</pub-id><pub-id pub-id-type="pmid">33397444</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swanton</surname><given-names>C</given-names></name><name><surname>McGranahan</surname><given-names>N</given-names></name><name><surname>Starrett</surname><given-names>GJ</given-names></name><name><surname>Harris</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Apobec enzymes: mutagenic fuel for cancer evolution and heterogeneity</article-title><source>Cancer Discovery</source><volume>5</volume><fpage>704</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-0344</pub-id><pub-id pub-id-type="pmid">26091828</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tisza</surname><given-names>MJ</given-names></name><name><surname>Pastrana</surname><given-names>DV</given-names></name><name><surname>Welch</surname><given-names>NL</given-names></name><name><surname>Stewart</surname><given-names>B</given-names></name><name><surname>Peretti</surname><given-names>A</given-names></name><name><surname>Starrett</surname><given-names>GJ</given-names></name><name><surname>Pang</surname><given-names>Y-YS</given-names></name><name><surname>Krishnamurthy</surname><given-names>SR</given-names></name><name><surname>Pesavento</surname><given-names>PA</given-names></name><name><surname>McDermott</surname><given-names>DH</given-names></name><name><surname>Murphy</surname><given-names>PM</given-names></name><name><surname>Whited</surname><given-names>JL</given-names></name><name><surname>Miller</surname><given-names>B</given-names></name><name><surname>Brenchley</surname><given-names>J</given-names></name><name><surname>Rosshart</surname><given-names>SP</given-names></name><name><surname>Rehermann</surname><given-names>B</given-names></name><name><surname>Doorbar</surname><given-names>J</given-names></name><name><surname>Ta’ala</surname><given-names>BA</given-names></name><name><surname>Pletnikova</surname><given-names>O</given-names></name><name><surname>Troncoso</surname><given-names>JC</given-names></name><name><surname>Resnick</surname><given-names>SM</given-names></name><name><surname>Bolduc</surname><given-names>B</given-names></name><name><surname>Sullivan</surname><given-names>MB</given-names></name><name><surname>Varsani</surname><given-names>A</given-names></name><name><surname>Segall</surname><given-names>AM</given-names></name><name><surname>Buck</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Discovery of several thousand highly diverse circular DNA viruses</article-title><source>eLife</source><volume>9</volume><elocation-id>e51971</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.51971</pub-id><pub-id pub-id-type="pmid">32014111</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Tisza</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Cenote-taker 2</data-title><version designator="2.1.2">2.1.2</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/mtisza1/Cenote-Taker2">https://github.com/mtisza1/Cenote-Taker2</ext-link></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tisza</surname><given-names>MJ</given-names></name><name><surname>Belford</surname><given-names>AK</given-names></name><name><surname>Domínguez-Huerta</surname><given-names>G</given-names></name><name><surname>Bolduc</surname><given-names>B</given-names></name><name><surname>Buck</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cenote-taker 2 democratizes virus discovery and sequence annotation</article-title><source>Virus Evolution</source><volume>7</volume><elocation-id>veaa100</elocation-id><pub-id pub-id-type="doi">10.1093/ve/veaa100</pub-id><pub-id pub-id-type="pmid">33505708</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toptan</surname><given-names>T</given-names></name><name><surname>Yousem</surname><given-names>SA</given-names></name><name><surname>Ho</surname><given-names>J</given-names></name><name><surname>Matsushima</surname><given-names>Y</given-names></name><name><surname>Stabile</surname><given-names>LP</given-names></name><name><surname>Fernández-Figueras</surname><given-names>M-T</given-names></name><name><surname>Bhargava</surname><given-names>R</given-names></name><name><surname>Ryo</surname><given-names>A</given-names></name><name><surname>Moore</surname><given-names>PS</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Survey for human polyomaviruses in cancer</article-title><source>JCI Insight</source><volume>1</volume><elocation-id>e85562</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.85562</pub-id><pub-id pub-id-type="pmid">27034991</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tye</surname><given-names>S</given-names></name><name><surname>Ronson</surname><given-names>GE</given-names></name><name><surname>Morris</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A fork in the road: where homologous recombination and stalled replication fork protection part ways</article-title><source>Seminars in Cell &amp; Developmental Biology</source><volume>113</volume><fpage>14</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2020.07.004</pub-id><pub-id pub-id-type="pmid">32653304</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vajdic</surname><given-names>CM</given-names></name><name><surname>van Leeuwen</surname><given-names>MT</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Cancer incidence and risk factors after solid organ transplantation</article-title><source>International Journal of Cancer</source><volume>125</volume><fpage>1747</fpage><lpage>1754</lpage><pub-id pub-id-type="doi">10.1002/ijc.24439</pub-id><pub-id pub-id-type="pmid">19444916</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Doorslaer</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Xirasagar</surname><given-names>S</given-names></name><name><surname>Maes</surname><given-names>P</given-names></name><name><surname>Kaminsky</surname><given-names>D</given-names></name><name><surname>Liou</surname><given-names>D</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Kaur</surname><given-names>R</given-names></name><name><surname>Huyen</surname><given-names>Y</given-names></name><name><surname>McBride</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The papillomavirus episteme: a major update to the papillomavirus sequence database</article-title><source>Nucleic Acids Research</source><volume>45</volume><fpage>D499</fpage><lpage>D506</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw879</pub-id><pub-id pub-id-type="pmid">28053164</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verhalen</surname><given-names>B</given-names></name><name><surname>Starrett</surname><given-names>GJ</given-names></name><name><surname>Harris</surname><given-names>RS</given-names></name><name><surname>Jiang</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Functional upregulation of the DNA cytosine deaminase APOBEC3B by polyomaviruses</article-title><source>Journal of Virology</source><volume>90</volume><fpage>6379</fpage><lpage>6386</lpage><pub-id pub-id-type="doi">10.1128/JVI.00771-16</pub-id><pub-id pub-id-type="pmid">27147740</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viarisio</surname><given-names>D</given-names></name><name><surname>Müller-Decker</surname><given-names>K</given-names></name><name><surname>Zanna</surname><given-names>P</given-names></name><name><surname>Kloz</surname><given-names>U</given-names></name><name><surname>Aengeneyndt</surname><given-names>B</given-names></name><name><surname>Accardi</surname><given-names>R</given-names></name><name><surname>Flechtenmacher</surname><given-names>C</given-names></name><name><surname>Gissmann</surname><given-names>L</given-names></name><name><surname>Tommasino</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Novel ß-HPV49 transgenic mouse model of upper digestive tract cancer</article-title><source>Cancer Research</source><volume>76</volume><fpage>4216</fpage><lpage>4225</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-0370</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viarisio</surname><given-names>D</given-names></name><name><surname>Müller-Decker</surname><given-names>K</given-names></name><name><surname>Accardi</surname><given-names>R</given-names></name><name><surname>Robitaille</surname><given-names>A</given-names></name><name><surname>Dürst</surname><given-names>M</given-names></name><name><surname>Beer</surname><given-names>K</given-names></name><name><surname>Jansen</surname><given-names>L</given-names></name><name><surname>Flechtenmacher</surname><given-names>C</given-names></name><name><surname>Bozza</surname><given-names>M</given-names></name><name><surname>Harbottle</surname><given-names>R</given-names></name><name><surname>Voegele</surname><given-names>C</given-names></name><name><surname>Ardin</surname><given-names>M</given-names></name><name><surname>Zavadil</surname><given-names>J</given-names></name><name><surname>Caldeira</surname><given-names>S</given-names></name><name><surname>Gissmann</surname><given-names>L</given-names></name><name><surname>Tommasino</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Beta HPV38 oncoproteins act with a hit-and-run mechanism in ultraviolet radiation-induced skin carcinogenesis in mice</article-title><source>PLOS Pathogens</source><volume>14</volume><elocation-id>e1006783</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006783</pub-id><pub-id pub-id-type="pmid">29324843</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vieira</surname><given-names>VC</given-names></name><name><surname>Leonard</surname><given-names>B</given-names></name><name><surname>White</surname><given-names>EA</given-names></name><name><surname>Starrett</surname><given-names>GJ</given-names></name><name><surname>Temiz</surname><given-names>NA</given-names></name><name><surname>Lorenz</surname><given-names>LD</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Soares</surname><given-names>MA</given-names></name><name><surname>Lambert</surname><given-names>PF</given-names></name><name><surname>Howley</surname><given-names>PM</given-names></name><name><surname>Harris</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B</article-title><source>MBio</source><volume>5</volume><elocation-id>e02234-14</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.02234-14</pub-id><pub-id pub-id-type="pmid">25538195</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallez</surname><given-names>Y</given-names></name><name><surname>Riedl</surname><given-names>SJ</given-names></name><name><surname>Pasquale</surname><given-names>EB</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Association of the breast cancer antiestrogen resistance protein 1 (BCAR1) and BCAR3 scaffolding proteins in cell signaling and antiestrogen resistance</article-title><source>The Journal of Biological Chemistry</source><volume>289</volume><fpage>10431</fpage><lpage>10444</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.541839</pub-id><pub-id pub-id-type="pmid">24584939</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Fu</surname><given-names>F</given-names></name><name><surname>Yan</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Geng</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>R</given-names></name><name><surname>Elias</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>RJ</given-names></name><name><surname>Feldman</surname><given-names>AS</given-names></name><name><surname>Blute</surname><given-names>ML</given-names></name><name><surname>Colvin</surname><given-names>RB</given-names></name><name><surname>Wu</surname><given-names>C-L</given-names></name><name><surname>Miao</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Viral integration in BK polyomavirus-associated urothelial carcinoma in renal transplant recipients: multistage carcinogenesis revealed by next-generation virome capture sequencing</article-title><source>Oncogene</source><volume>39</volume><fpage>5734</fpage><lpage>5742</lpage><pub-id pub-id-type="doi">10.1038/s41388-020-01398-6</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warburton</surname><given-names>A</given-names></name><name><surname>Redmond</surname><given-names>CJ</given-names></name><name><surname>Dooley</surname><given-names>KE</given-names></name><name><surname>Fu</surname><given-names>H</given-names></name><name><surname>Gillison</surname><given-names>ML</given-names></name><name><surname>Akagi</surname><given-names>K</given-names></name><name><surname>Symer</surname><given-names>DE</given-names></name><name><surname>Aladjem</surname><given-names>MI</given-names></name><name><surname>McBride</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>HPV integration hijacks and multimerizes a cellular enhancer to generate a viral-cellular super-enhancer that drives high viral oncogene expression</article-title><source>PLOS Genetics</source><volume>14</volume><elocation-id>e1007179</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1007179</pub-id><pub-id pub-id-type="pmid">29364907</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>CJ</given-names></name><name><surname>Van Doorslaer</surname><given-names>K</given-names></name><name><surname>Pandey</surname><given-names>A</given-names></name><name><surname>Espinosa</surname><given-names>JM</given-names></name><name><surname>Pyeon</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015a</year><article-title>Role of the host restriction factor APOBEC3 on papillomavirus evolution</article-title><source>Virus Evolution</source><volume>1</volume><elocation-id>vev015</elocation-id><pub-id pub-id-type="doi">10.1093/ve/vev015</pub-id><pub-id pub-id-type="pmid">27570633</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>CJ</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Guo</surname><given-names>K</given-names></name><name><surname>Griffin</surname><given-names>LM</given-names></name><name><surname>Westrich</surname><given-names>JA</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Lambert</surname><given-names>PF</given-names></name><name><surname>Santiago</surname><given-names>ML</given-names></name><name><surname>Pyeon</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015b</year><article-title>Apobec3A functions as a restriction factor of human papillomavirus</article-title><source>Journal of Virology</source><volume>89</volume><fpage>688</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1128/JVI.02383-14</pub-id><pub-id pub-id-type="pmid">25355878</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>C.J</given-names></name><name><surname>Westrich</surname><given-names>JA</given-names></name><name><surname>Doorslaer</surname><given-names>KV</given-names></name><name><surname>Pyeon</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Roles of APOBEC3A and APOBEC3B in human papillomavirus infection and disease progression</article-title><source>Viruses</source><volume>9</volume><elocation-id>233</elocation-id><pub-id pub-id-type="doi">10.3390/v9080233</pub-id><pub-id pub-id-type="pmid">28825669</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilm</surname><given-names>A</given-names></name><name><surname>Aw</surname><given-names>PPK</given-names></name><name><surname>Bertrand</surname><given-names>D</given-names></name><name><surname>Yeo</surname><given-names>GHT</given-names></name><name><surname>Ong</surname><given-names>SH</given-names></name><name><surname>Wong</surname><given-names>CH</given-names></name><name><surname>Khor</surname><given-names>CC</given-names></name><name><surname>Petric</surname><given-names>R</given-names></name><name><surname>Hibberd</surname><given-names>ML</given-names></name><name><surname>Nagarajan</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets</article-title><source>Nucleic Acids Research</source><volume>40</volume><fpage>11189</fpage><lpage>11201</lpage><pub-id pub-id-type="doi">10.1093/nar/gks918</pub-id><pub-id pub-id-type="pmid">23066108</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>AL</given-names></name><name><surname>Schrecengost</surname><given-names>RS</given-names></name><name><surname>Guerrero</surname><given-names>MS</given-names></name><name><surname>Thomas</surname><given-names>KS</given-names></name><name><surname>Bouton</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Breast cancer antiestrogen resistance 3 (BCAR3) promotes cell motility by regulating actin cytoskeletal and adhesion remodeling in invasive breast cancer cells</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e65678</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0065678</pub-id><pub-id pub-id-type="pmid">23762409</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zapatka</surname><given-names>M</given-names></name><name><surname>Borozan</surname><given-names>I</given-names></name><name><surname>Brewer</surname><given-names>DS</given-names></name><name><surname>Iskar</surname><given-names>M</given-names></name><name><surname>Grundhoff</surname><given-names>A</given-names></name><name><surname>Alawi</surname><given-names>M</given-names></name><name><surname>Desai</surname><given-names>N</given-names></name><name><surname>Sültmann</surname><given-names>H</given-names></name><name><surname>Moch</surname><given-names>H</given-names></name><collab>PCAWG Pathogens</collab><name><surname>Cooper</surname><given-names>CS</given-names></name><name><surname>Eils</surname><given-names>R</given-names></name><name><surname>Ferretti</surname><given-names>V</given-names></name><name><surname>Lichter</surname><given-names>P</given-names></name><collab>PCAWG Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>The landscape of viral associations in human cancers</article-title><source>Nature Genetics</source><volume>52</volume><fpage>320</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1038/s41588-019-0558-9</pub-id><pub-id pub-id-type="pmid">32025001</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Fujimoto</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wedge</surname><given-names>DC</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Seth</surname><given-names>S</given-names></name><name><surname>Chow</surname><given-names>C-W</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Gumbs</surname><given-names>C</given-names></name><name><surname>Gold</surname><given-names>KA</given-names></name><name><surname>Kalhor</surname><given-names>N</given-names></name><name><surname>Little</surname><given-names>L</given-names></name><name><surname>Mahadeshwar</surname><given-names>H</given-names></name><name><surname>Moran</surname><given-names>C</given-names></name><name><surname>Protopopov</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>William</surname><given-names>WN</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Heymach</surname><given-names>JV</given-names></name><name><surname>Hong</surname><given-names>WK</given-names></name><name><surname>Swisher</surname><given-names>S</given-names></name><name><surname>Wistuba</surname><given-names>II</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing</article-title><source>Science</source><volume>346</volume><fpage>256</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1126/science.1256930</pub-id><pub-id pub-id-type="pmid">25301631</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.82690.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wallace</surname><given-names>Nicholas</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05p1j8758</institution-id><institution>Kansas State University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2021.11.11.21266080" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2021.11.11.21266080"/></front-stub><body><p>This work provides a compelling case that viral origins of bladder cancer should be more carefully considered. Specifically, the clonogenic expression of viral oncogenes in these tumors combined with the lower than expected prevalence of major tumor suppressor (p53 and pRB) provides strong evidence for the authors' assertions. Ultimately, it will be important to follow up this work and I look forward to seeing those next steps.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.82690.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Wallace</surname><given-names>Nicholas</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05p1j8758</institution-id><institution>Kansas State University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Wallace</surname><given-names>Nicholas</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05p1j8758</institution-id><institution>Kansas State University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.11.11.21266080">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2021.11.11.21266080v2">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Evidence for Virus-Mediated Oncogenesis in Bladder Cancers Arising in Solid Organ Transplant Recipients&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, including Nicholas Wallace as Reviewing Editor and Reviewer #2, and the evaluation has been overseen by Wafik El-Deiry as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>(1) Despite showing strong evidence that viruses are altering the tumor cell environment, it is unclear if these changes are necessary for tumorigenesis. The heterogeneity of the LT expression suggests that the presence of the viral DNA and RNA may not be enough to assess whether it is actively contributing to the tumor. Is an increased frequency of viral protein staining linked with any evidence of an active contribution to tumorigenesis (fewer tumor-suppressor/oncogene mutations). that they reduced mutations in tumor suppressors. This might be easiest to assess with the tumors that have oncogenic HPV DNA. (If those tumors lacked p53 and RB mutations, it would support a causative role for the virus.) For BKPyV+ cancers, is the virus playing a role as a driver, hit and run, or by-stander as described in Dalianis et al., 2013 (https://pubmed.ncbi.nlm.nih.gov/23357733/).</p><p>(2) The data presented here and previously published data (https://doi.org/10.1002/path.5012) hint at Chromosome 1 as a potential &quot;hot spot&quot; for viral integration. Alternatively, this could be due to the larger relative size of the chromosome or some other feature of the chromosome. This should be discussed.</p><p>(3) There are multiple places where the organization and presentation of the data needs to be improved. These are noted in individual reviewer comments provided below.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>In general, there seem to be multiple mistakes in terms of sample numbers, figure references and figure legends, which complicated the review extensively. In addition, in many of the shown data, it was not clear why only specific samples have been chosen or why some samples have just been left out or have been &quot;forgotten&quot;. Moreover, for some of the statements in the Results sections, literature references are missing. Abbreviations should always be explained and be consistent throughout the manuscript and according to current state of the art (DeCaprio, J. A., et al. (2020). Fields Virolgy: DNA Viruses). All of these points need to be properly addressed before publishing the manuscript.</p><p>Title:</p><p>The title should be adapted as data does not support &quot;viral-mediated oncogenesis&quot;.</p><p>Related to Table 1:</p><p>The table should be adapted for a better overview with characteristics and statistics being clearly labeled (see below). Suggest structuring it as follows: age in years at diagnosis, years from transplant to diagnosis, race, sex, transplanted organ, grade, summary stage (also following text).</p><p>Characteristic Statistic</p><p>Median IQR</p><p>Age in years at diagnosis</p><p>N %</p><p>Race</p><p>In the category &quot;race&quot; seems 1 patient missing as the sum only results in 42 cases. Please adapt the table and text.</p><p>Page 7 line 3-6:</p><p>It is not clear why not 43 primary tumors have been analyzed (corresponding to Table 1 and Figure 1)? Why are numbers between WGS and total RNAseq different? From Figure 1 it seems that multiple samples have been used from one patient, is this correct? If yes, this is not clear in the results description, please adapt. What does normal tissue mean = healthy?</p><p>Page 7 line 18 and Figure S1:</p><p>Please reference Figure S1 in the text. Please show coverage plots of TBC07 and separate runs of TBC03 (as for TBC09).</p><p>Figure 1 and Materials and methods:</p><p>What does &quot;no data&quot; mean? Was there no material available or was the quantity/quality of DNA not enough? Please clarify this in the text and Materials and methods.</p><p>&quot;We obtained twenty 10-micron sections from formal-fixed paraffin-embedded (FFPE) blocks for cases with available material.&quot; How does that fit with Table 1 talking about 43 primary tumors?</p><p>How do the authors explain that for some tumors DNA signatures but no latency dependent transcripts could be detected? Please integrate in the text.</p><p>Material and methods:</p><p>How long were the DNA and RNA samples stored at 4{degree sign}C? Prolonged storage at 4{degree sign}C, especially for RNA samples, could contribute to low sample quality. Please adapt in the material and methods.</p><p>Which polyomavirus LTags are recognized by the used antibody? Please mention.</p><p>Related to Table 2:</p><p>Please sort Table 2 according to the most frequent chromosome location so overrepresentation of e.g., chromosome 1 is obvious. Might this integration sites be a contamination or a real hot-spot? Please discuss.</p><p>All abbreviations used in the table should be explained.</p><p>Page 9 line 10:</p><p>How was tumor purity immunohistochemically assessed? Should be explained in the Materials and methods section.</p><p>Figure 4B:</p><p>How were the stabilized counts calculated? This should be described in the Materials and methods.</p><p>Was TBC01 included in the BKPyV positive tumors? There should be only 9 BKPyV-positive tumors rather than 10. The authors should show one graph with exclusion of TBC01.</p><p>Figure S2:</p><p>Wrong figure reference and figure legend. It is very hard to interpret the data if figure references and legends are not correctly cited. Authors should carefully review the whole manuscript.</p><p>Page 11 lines 9-15:</p><p>Is there any figure associated to the statement? It is unclear what this result means.</p><p>Figure 5:</p><p>TBC02 seems to be missing in the BKPyV positive tumors. All BKPyV-negative tumors and all 43 primary tumors should be displayed.</p><p>Page 12 lines 6-12 and Figure S3:</p><p>Paragraph should refer to Figure S3 and not S4. &quot;A possible HPV51 integration site…&quot;: there is no data showing that.</p><p>Figure 6A:</p><p>What are the black bars representing? Why is TBC36 now BKPyV positive? Why is Figure 1 showing EBV but Figure 6 not? Why is Figure 6 showing TTV but Figure 1 not? Please explain and adapt.</p><p>Figure 6B:</p><p>Please show this analysis also for HPV-positive tumors.</p><p>Figure 6E:</p><p>It is suggested that the results are sorted according to the percentages and to cluster all BKPyV-positive tumors together.</p><p>Page 16 lines 1-22:</p><p>Paragraph about APOBUCK3B seems to be overrepresented in the discussion and consistency in statements failed. Some information is non-informative or even highly speculative. This paragraph should be extensively revised.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.82690.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>(1) Despite showing strong evidence that viruses are altering the tumor cell environment, it is unclear if these changes are necessary for tumorigenesis. The heterogeneity of the LT expression suggests that the presence of the viral DNA and RNA may not be enough to assess whether it is actively contributing to the tumor. Is an increased frequency of viral protein staining linked with any evidence of an active contribution to tumorigenesis (fewer tumor-suppressor/oncogene mutations). that they reduced mutations in tumor suppressors. This might be easiest to assess with the tumors that have oncogenic HPV DNA. (If those tumors lacked p53 and RB mutations, it would support a causative role for the virus.) For BKPyV+ cancers, is the virus playing a role as a driver, hit and run, or by-stander as described in Dalianis et al., 2013 (https://pubmed.ncbi.nlm.nih.gov/23357733/).</p></disp-quote><p>We thank the reviewers for their thoughtful review. Viral oncoprotein heterogeneity has previously been reported for HPV and MCPyV and can be affected by both methodology and biology, for example tumor hypoxia has been shown to affect E6 and E7 expression. Our evidence for clonal integration in primary tumors and a metastasis and recurrent helicase-inactivating mutations support selection in tumorigenesis. As suggested, in Figure 6 we indeed show that no BKPyV-positive or HPV-positive tumor harbored mutations in RB1. Additionally, only one BKPyV-positive tumor and none of the HPV-positive tumors had a mutation in TP53. We have added further emphasis to this point on page 14,</p><p>“None of the HPV-positive tumors with WGS harbored mutations in <italic>TP53</italic> or <italic>RB1</italic>. Similarly, none of the polyomavirus-positive tumors harbored mutations in <italic>RB1</italic> and only TBC08 had a frameshift mutation in <italic>TP53</italic>.”</p><p>We have also added speculation about the unique aspects of TBC01:</p><p>“This tumor likely represents a passenger infection of an existing tumor. Future studies should investigate the hypothesis that passenger infections might play an oncomodulatory role in tumor development.”</p><disp-quote content-type="editor-comment"><p>(2) The data presented here and previously published data (https://doi.org/10.1002/path.5012) hint at Chromosome 1 as a potential &quot;hot spot&quot; for viral integration. Alternatively, this could be due to the larger relative size of the chromosome or some other feature of the chromosome. This should be discussed.</p></disp-quote><p>In the current study, the events on chromosome 1 do not represent a hotspot since all of the integration events are from one patient and within 1000 bp of each other. These events instead appear to represent a single integration event with complex rearrangements. Two observations of integration on this large chromosome is not suggestive of a hotspot.</p><disp-quote content-type="editor-comment"><p>(3) There are multiple places where the organization and presentation of the data needs to be improved. These are noted in individual reviewer comments provided below.</p></disp-quote><p>We have addressed this and corrected the supplemental table order, which was due to a previous version being uploaded with the submission. Please see the detailed responses to individual comments.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>In general, there seem to be multiple mistakes in terms of sample numbers, figure references and figure legends, which complicated the review extensively. In addition, in many of the shown data, it was not clear why only specific samples have been chosen or why some samples have just been left out or have been &quot;forgotten&quot;. Moreover, for some of the statements in the Results sections, literature references are missing. Abbreviations should always be explained and be consistent throughout the manuscript and according to current state of the art (DeCaprio, J. A., et al. (2020). Fields Virolgy: DNA Viruses). All of these points need to be properly addressed before publishing the manuscript.</p></disp-quote><p>We apologize for this error and thank Reviewer #1 for pointing it out. It appears that a previous version of the supplemental material was uploaded with this manuscript, which led to most supplemental materials being off by one. We have checked the text regarding the issues raised by the reviewer, and we added references and defined abbreviations where we thought these changes were indicated.</p><disp-quote content-type="editor-comment"><p>Title:</p><p>The title should be adapted as data does not support &quot;viral-mediated oncogenesis&quot;.</p></disp-quote><p>We agree with Reviewer #1’s view that the data can be seen as falling short of conclusive proof of virus-mediated oncogenesis. But the finding of clonally integrated viruses in tumors and their metastases, the detection of distinctive transcriptomic signatures, and the absence of mutations in TP53 and RB1 – are accepted traditional lines of evidence for virus-mediated oncogenesis (for more detail, see: https://pubmed.ncbi.nlm.nih.gov/31336246/). We believe that starting the title with “Evidence for…” provides readers with an accurate description of the type of data that the manuscript is reporting without indicating that we are providing definitive proof.</p><disp-quote content-type="editor-comment"><p>Related to Table 1:</p><p>The table should be adapted for a better overview with characteristics and statistics being clearly labeled (see below). Suggest structuring it as follows: age in years at diagnosis, years from transplant to diagnosis, race, sex, transplanted organ, grade, summary stage (also following text).</p><p>Characteristic Statistic</p><p>Median IQR</p><p>Age in years at diagnosis</p><p>N %</p><p>Race</p></disp-quote><p>We have reordered the table to bundle the common patient statistics (i.e. N % and Median IQR, respectively) together and clearly labeled the columns above the statistics.</p><disp-quote content-type="editor-comment"><p>In the category &quot;race&quot; seems 1 patient missing as the sum only results in 42 cases. Please adapt the table and text.</p></disp-quote><p>This has been corrected.</p><disp-quote content-type="editor-comment"><p>Page 7 line 3-6:</p><p>It is not clear why not 43 primary tumors have been analyzed (corresponding to Table 1 and Figure 1)? Why are numbers between WGS and total RNAseq different? From Figure 1 it seems that multiple samples have been used from one patient, is this correct? If yes, this is not clear in the results description, please adapt. What does normal tissue mean = healthy?</p></disp-quote><p>As described in the Materials and methods on page 22, lines 24-25 and page 24, lines 9-10 samples that didn’t yield enough nucleic acids for library preparation were not sequenced. This should hopefully be clearer with the addition of the suggested Supplemental table 1 (supplementary file 1a) checkerboard. Please see Results page 7, line 18-19, and Figure 2 legend. We have added, on page 7 line 4, an additional definition of normal as “histologically non-malignant.” The legends for Figures 2 and 6 also explain that for samples TBC03, TBC09, and TBC28 two separate sections of the tumor were sequenced.</p><disp-quote content-type="editor-comment"><p>Page 7 line 18 and Figure S1:</p><p>Please reference Figure S1 in the text. Please show coverage plots of TBC07 and separate runs of TBC03 (as for TBC09).</p></disp-quote><p>This has been added.</p><disp-quote content-type="editor-comment"><p>Figure 1 and Materials and methods:</p><p>What does &quot;no data&quot; mean? Was there no material available or was the quantity/quality of DNA not enough? Please clarify this in the text and Materials and methods.</p></disp-quote><p>See the response to comment 4 and changes on Page 7 lines 3-6.</p><disp-quote content-type="editor-comment"><p>&quot;We obtained twenty 10-micron sections from formal-fixed paraffin-embedded (FFPE) blocks for cases with available material.&quot; How does that fit with Table 1 talking about 43 primary tumors?</p></disp-quote><p>This text is describing the amount of sample collected per case. This has been revised to read:</p><p>“We obtained twenty 10-micron sections from formal-fixed paraffin-embedded (FFPE) blocks for each specimen with available material.”</p><disp-quote content-type="editor-comment"><p>How do the authors explain that for some tumors DNA signatures but no latency dependent transcripts could be detected? Please integrate in the text.</p></disp-quote><p>We are uncertain about what the reviewer means by “DNA signatures” and “latency-dependent transcripts.” If we infer that some tumors have mutational signatures associated with viruses but do not have viral transcripts, our sense – as stated in the Discussion – is that this might represent transient suppression of viral transcription or it could reflect hypothetical hit-and-run effects.</p><disp-quote content-type="editor-comment"><p>Material and methods:</p><p>How long were the DNA and RNA samples stored at 4{degree sign}C? Prolonged storage at 4{degree sign}C, especially for RNA samples, could contribute to low sample quality. Please adapt in the material and methods.</p><p>Which polyomavirus LTags are recognized by the used antibody? Please mention.</p></disp-quote><p>The manuscript has been revised to note that all samples were processed within one month of receipt into our laboratory. Of note, with FFPE source material and this extraction method, RNAs are already highly fragmented immediately after extraction. We have observed that fragmentation does not significantly increase with storage time, as RNA integrity numbers are consistently between 2 to 4 immediately after RNA extraction. Additionally, the Takara total RNAseq kit used here takes advantage of the fragmented nature of the input RNA by not including a fragmentation step for FFPE RN. Subsequent library size selection removes very small fragments.</p><p>For the PAb416 antibody used for IHC, we have added the following text to the methods:</p><p>“clone Pab416 (Σ Millipore, cat. DP02), which detects LTag from multiple polyomaviruses, including SV40, BKPyV, JCPyV, WU, KI, 6, 7, 10, and 11 (84).”</p><disp-quote content-type="editor-comment"><p>Related to Table 2:</p><p>Please sort Table 2 according to the most frequent chromosome location so overrepresentation of e.g., chromosome 1 is obvious. Might this integration sites be a contamination or a real hot-spot? Please discuss.</p><p>All abbreviations used in the table should be explained.</p></disp-quote><p>We appreciate the comment, but we feel that sorting by chromosome will make the table difficult to interpret. Currently, it is sorted by patient ID, which we hope will make it easier for readers to recognize that all of the chromosome 1 integration junctions are from the same patient and within about 1000 basepairs of each other. We do not infer that chromosome 1 is a common hotspot; rather, within that patient there is a complex rearrangement that occurred on chromosome 1. Abbreviations have been added.</p><disp-quote content-type="editor-comment"><p>Page 9 line 10:</p><p>How was tumor purity immunohistochemically assessed? Should be explained in the Materials and methods section.</p></disp-quote><p>Tumor purity was determined by H and E staining and review by our pathologist. A description has been added to Materials and methods, page 22 line 26 and page 10, line 14.</p><disp-quote content-type="editor-comment"><p>Figure 4B:</p><p>How were the stabilized counts calculated? This should be described in the Materials and methods.</p></disp-quote><p>Our method for stabilizing the counts is described in Figure 4 legend: “Variance stabilized counts for APOBEC3B from DESeq2.” and in Material and Methods page 26, line 20.</p><disp-quote content-type="editor-comment"><p>Was TBC01 included in the BKPyV positive tumors? There should be only 9 BKPyV-positive tumors rather than 10. The authors should show one graph with exclusion of TBC01.</p></disp-quote><p>This plot also contained the metastatic tumor of TBC06. We have now removed the TBC06 metastatic tumor and highlighted TBC01 in this plot so readers can discern its difference versus the other BKPyV-positive tumors.</p><disp-quote content-type="editor-comment"><p>Figure S2:</p><p>Wrong figure reference and figure legend. It is very hard to interpret the data if figure references and legends are not correctly cited. Authors should carefully review the whole manuscript.</p></disp-quote><p>We thank Reviewer #1 for catching our inadvertent uploading of the wrong Supplementary files during the submission process. The correct supplements have been uploaded for the revision.</p><disp-quote content-type="editor-comment"><p>Page 11 lines 9-15:</p><p>Is there any figure associated to the statement? It is unclear what this result means.</p></disp-quote><p>We’ve added Figure 4-supplement 2 to support this statement. Virus integration commonly increases the expression of adjacent host genes, which can be an important selective pressure for a particular integration event. However, our one case with observed increased RNA coverage seems to originate from an amplification of a relatively small section host DNA rather than increased expression of the entire gene.</p><disp-quote content-type="editor-comment"><p>Figure 5:</p><p>TBC02 seems to be missing in the BKPyV positive tumors. All BKPyV-negative tumors and all 43 primary tumors should be displayed.</p></disp-quote><p>TBC02 has been added to panel B. All additional primary tumors with WGS have been added as panel E.</p><disp-quote content-type="editor-comment"><p>Page 12 lines 6-12 and Figure S3:</p><p>Paragraph should refer to Figure S3 and not S4. &quot;A possible HPV51 integration site…&quot;: there is no data showing that.</p></disp-quote><p>We apologize for the misordered supplement file. We have now added a panel showing evidence for HPV51 integration to Figure S5.</p><disp-quote content-type="editor-comment"><p>Figure 6A:</p><p>What are the black bars representing? Why is TBC36 now BKPyV positive? Why is Figure 1 showing EBV but Figure 6 not? Why is Figure 6 showing TTV but Figure 1 not? Please explain and adapt.</p></disp-quote><p>Black bars indicate that there is no determined etiologic agent or virus, which has now been added to the figure legend. Some of the bars were incorrectly colored in 6A and have been corrected. The calls and colors in 6C and 6E are correct. TTV was detected through a different method to look for divergent sequences, so it cannot readily be shown in Figure 1; this is explained in the results and methods. The very low depth and percent coverage of the EBV reads detected in TBC07 and TBC03 tumors and absence of RNA reads suggest that these are likely incidental infections; therefore, we did not classify these tumors as EBV positive in Figure 6.</p><disp-quote content-type="editor-comment"><p>Figure 6B:</p><p>Please show this analysis also for HPV-positive tumors.</p></disp-quote><p>This analysis was conducted on all tumors for which we were able to generate WGS data, including the HPV-positive tumors.</p><disp-quote content-type="editor-comment"><p>Figure 6E:</p><p>It is suggested that the results are sorted according to the percentages and to cluster all BKPyV-positive tumors together.</p></disp-quote><p>The results are sorted by the calculated selection enrichment by dNdScv R package (more details have been added to the methods on page 27), which takes into account total synonymous, missense, indel, and nonsynonymous mutations in a sample and gene sizes. This is an important calculation because simply analyzing mutations by frequency almost always results in the identification of very large genes (TTN is a key example) rather than finding loci with evidence for positive selection.</p><disp-quote content-type="editor-comment"><p>Page 16 lines 1-22:</p><p>Paragraph about APOBUCK3B seems to be overrepresented in the discussion and consistency in statements failed. Some information is non-informative or even highly speculative. This paragraph should be extensively revised.</p></disp-quote><p>In our view, an important purpose of scientific Discussion sections is to present plausible ideas that might help readers generate experimentally testable hypotheses and start building on the results. APOBEC3B has been shown to be upregulated by BKPyV infection and specifically by the activity of the suppression of the DREAM complex by LTag. APOBEC3-associated mutations are the second most abundant mutagenic process in all cancers and also the dominant mutation signature in bladder cancers arising in the general population. Furthermore, APOBEC3 mutagenesis has shaped the evolution of the BKPyV genome. It is of considerable interest to the field whether BKPyV infection contributes to APOBEC3 mutagenesis of the host genome in infected cells (see PMID 35194151). We see this as an important future direction for the field. For these reasons, we believe it is appropriate to provide a thorough discussion on APOBEC3B and have therefore not shortened the text.</p></body></sub-article></article>